Advanced diagnostics, genomics and precision medicine

Showing 1 - 41 of 41
Filters
Innovation 'Elevator Pitch':
Software that automatically engages with stakeholders to track performance & risk and identify continuous improvement opportunities in campaigns and/or contracted out services.
Overview of Innovation:
Do you find it difficult to track and measure contract or campaign performance? Compared to well-managed contracts/campaigns, unmanaged or poorly managed contracts/campaigns can lead to costly inefficiencies, poor performance and an increase in risk.
ContractsWise is now offering its innovative, cloud-based contract management tool: ECMS, (available via the Crown Commercial Services G-Cloud Framework Agreement if required). Designed by experienced contract managers, ECMS can increase performance and savings, improve service quality, and mitigate risk, with an automatically backed-up database to prevent loss of data.
Some of ECMS’s features include:
  • A  register to record all contracts/campaigns and associated documents in a secure database
  • A dashboard that can be individually configured for each user, with information on performance and risks
  • Compatibility with any device with a web-connection, including tablets and smartphones, without the need to download additional software
  • Actively and automatically engage with stakeholders.
For those who don’t need all of ECMS’s features, there’s ECAS, an administration system that is scalable to your needs and will help improve control of information and documentation.
ECAS’s Entry Level Plan features include:
  • Searchable database of your information and documents
  • Automated reminders for important dates
  • Secure cloud storage with automated data back-up which frees up physical space
  • Archive old information
  • Online tutorials and help documents.
All of ECAS’s features are included in ECMS.
Understanding contract management and how to improve performance can be difficult, which is why ContractsWise also run an online training course: An Introduction to Contract Management, which combines theory and best practice to give you a comprehensive understanding of the subject.
For more information on the ways that ContractsWise can help please visit www.contractswise.com
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
There is an increasing body of evidence that shows that organisations incur significant unplanned costs, don't achieve expected savings or service quality as a result of a lack of effective contract/campaign management.
Research by the International Association of Commercial and Contract Management (IACCM) has quantified the value of these losses at the equivalent of 9.2% of revenue.
All organisations want to achieve the maximum value for every pound spent but in the NHS this is critical. ContractsWise provides low cost tools that will enable the NHS ensure that best value is achieved, risks are identified and mitigated and opportunities for continuous improvement are identified.
A business case template is available to download for free from our website www.contractswise.com and the return on investment will include: avoidance of unplanned costs; never miss a contract termination or renewal negotiation opportunity; realise planned cost savings or revenue improvements; reduce administration time; improve internal and external stakeholder relationships; redice risks; improve compliance; improve reporting.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Users of the NHS in the West Midlands will receive improved services and will be able to contribut eto the continuous improvement of services.
Providers of services will have greater control over their budgeted expenditure or revenue.
Current and planned activity: 
Our software has recently been adopted by Western Sussex NHS Trust.
Following a full review of software available on the market The Chartrered Institute of Procurement and Supply (CIPS) chose our software and has been operating with it since February 2015.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:

Being cloud based with minimal training required,the software can be easily scaled nationally and internationally.

Measures:

The goal is to maximise the performance and minimise the risks associated with the delivery of services by a 3rd party. Maximising performance will ensure that value for money is also maximised and will increase end user satisfaction rates. Minimising risks will reduce the possibility of unplanned costs that have not been budgetted for and will help ensure that any planned savings are actually delivered.
Users of the software will be able to continually measure performance and risk using the tools and dashboard built into the software. The users have full control over what it wants to measure so these can include quality, safety, cost and people.
ContractsWise limited will also measure the satisfaction of our customers through engagement with key stakeholders and work with them to maximise the benefits achieved by using the software in order to generate compelling case studies.

Adoption target:

Any organisation, part of an organisation or project whose measure of success relies upon the delivery of services from one or many 3rd parties.

Read more
Hide details
Noel Green 14/12/2015 - 14:53 Detailed Submission 1 comment
2.8
4
Votes
-99999
Innovation 'Elevator Pitch':
Greenbox is a mutlifunctional data capture device which can be used for the verification and registration of both staff and patients.
Overview of Innovation:
Greenbox is a desktop-sized device which connects through USB to a laptop or desktop PC, it's has huge potential in patient/staff enrollment as well as verification and registration.
 
Greenbox consists of 5 forms of data capture methods: a high resolution digital camera, a smart card reader, digital biometric thumb-print scanner, digital signature pad and document scanner. Paired with the GreenForm software, it is a powerful tool in the creation of forms. The forms which can be customised to be populated with any information required use the forms of data capture within Greenbox to help populate the forms. Forms can be used during the assessment of patients prior to surgery, in A&E departments during the diagnosis of patients and even for the verification of patients prescribed with restricted drugs.
 
Greenbox has implemented throughout clinics in Pretorius, South Africa, to counteract fraud related incidents and verify the correct patients receive the correct drugs. This has been done to counteract South Africa’s street-drug problem and has streamlined patient enrollment and verification within Pretorius. Greenbox has also been implemented within the security sector and education sector with customers who required staff and student screening, registration and verification. Greenbox is a bespoke product which allows a degree of customisability. Features can be remove and the box itself can display anything on the screen such as the NHS logo.
 
Pairing Greenbox and GreenForm with a document management system allows the streamlining of any forms or records. Workflow can perform optical character recognition and using a complex set of rules can allocate documents to users for approval, archive documents where needed and even automatically send documents to their correct location with no user input needed. This ergonomic solution is amplified as documents are digitalised, reducing paper costs and reducing storage space.
 
GreenDoc Technologies is a solution like no other, a one-step solution to compliance. To discuss this product further or to discuss its potential please call us on 01785 785 655. Likewise email us on admin@ascot-solutions.co.uk to discuss further.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Advanced diagnostics, genomics and precision medicine / Education, training and future workforce / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
3
Read more
Hide details
Ross Putman 01/02/2016 - 18:12 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Proven in practice with NHS Pathology Laboratories, Pathology Manager delivers complete document management  support for all pathology process and works in partnership with any existing LIMS, PAS or Order Comms systems.
Overview of Innovation:
Complete Document Management for Pathology Departments to enable access too, and the sharing of information.
A proven scanning, barcode recognition and metadata tagging system for all paper forms used across a Pathology Department with instant retrieval & viewing from a web browser and via integration with any existing Pathology LIMS plus additional options for incorporating all other paper and digitally generated documents.
Developed in collaboration with NHS Pathology Laboratories, Pathology Manager delivers complete document management support for the whole pathology process. It enables the scanning of pathology request forms & paper documents and ingestion of digital files all into one system with intelligent barcode recognition and easy application of metadata plus instant search, retrieval & viewing directly over the organisation's network and from within an existing LIMS or PAS. It is 'plug & play' and very (very) affordable.

Uniquely with Pathology Manager, all documents - scanned paper, digitally generated (e.g. Word), emails, data reports, etc - are seen together via a Single Unified View (simultaneous viewing whatever their file type). And with instant searching, filtering and reporting plus automated alerting, auditing and monitoring, full document management across all pathology activities is ensured.

Pathology Manager works in partnership with existing LIMS (Laboratory Information Management Systems) like Clinisys MasterLab or Winpath, StarLIMS and Telepath (and any PAS) in support of all the pathology processes.

For additional information on features and benefits - Please visit:
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Helping Pathology save costs
  • There is no limit to the number or volume of scans generated (i.e. there is no extra 'cost per image' as with most other scanning software)
  • There is no limit on the number of users
  • There is no limit to the volume of documents made available for search & retrieval
  • Instantly reduces paper storage space and improves process efficiency
  • Pathology Manager is significantly more affordable than any alternative whilst providing 'best of breed' features & functionality
Essentially, with Pathology Manager both the Cost of Purchase and the Cost of Ownership are significantly better than any alternative 

"Pathology Manager has allowed us to improve the efficiency, accuracy and speed of some of the key services provided by the Pathology Department.  It has provided a highly cost effective, high performance solution to a long standing information management challenge".   
Worcestershire NHS Pathology


For additional information on features and benefits - Please visit:
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • Folding Space would like to extend the use of our software across the whole of the West Midlands as this would allow us to grow and develop not only our service here in the region but also to excelerate our software development and its facilities, products and our company.
Current and planned activity: 
  • Currently selling Pathology Manager into the NHS with adoption of the product within two trust within the West Midlands region
    • Walsall Healthcare NHS Trust
    • Worcester Health and Care NHS Trust
    • North Midlands NHS
       
  • Folding Space is working in conjunction with multiple trusts to pilot and develop a new product that will be market ready in April 2016. This project has been funded by Innovate UK
Planned / required activity
  • Increased procurement / adoption of Pathology Manager within the West Midlands region
     
  • Folding Space currently have another medical product in development that will be ready for commercialisation in April, further support and interest in the product will be sought at that time
What is the intellectual property status of your innovation?:
Folding Space owns all its IPR
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:

Yes

Measures:

Revenues

Adoption target:

UK wide, commercial and public sector

Read more
Hide details
Chris Massey 29/02/2016 - 14:37 Detailed Submission Login or Register to post comments
3.3
3
Votes
-99999
Innovation 'Elevator Pitch':
The MicroEye system delivers simple, reliable and highly cost-effective continuous glucose, lactate and many other blood analyte samples capable of measurement by stand-alone external diagnostic equipment for display on laptop or bed-head monitor.
Overview of Innovation:
MicroEye transforms point-of-care blood sampling from ‘point in time’ to automated continuous monitoring of a vast range of potential analytes, for improved outcomes in critical care. MicroEye is an easy to use device that is inserted using common peripheral venous catheters. It delivers dialysate to an external sensor system which means the blood can stay in the patient and real-time data is available to standalone monitors, bed head array systems or hospital information systems.

MicroEye is approved for use in the peripheral vascular system and in subcutaneous, intramuscular and adipose tissue. Most small water-soluble molecules can be monitored, and many including glucose and lactate can be monitored in real time, helping to improve clinical outcomes in a range of specialties including intensive care, cardiology, surgery, emergency medicine, paediatrics and neonatology.

Glucose Control
Continuous and automated real-time online monitoring of blood glucose using MicroEye® may provide accurate data for improved management of some patient groups. Although around 10 per cent of intensive care patients may be diabetic, the incidence of stress-induced hyperglycaemia has been reported to range from 30 to 100 per cent. Effective control of blood glucose levels reduces the incidence of hyperglycaemia and hypoglycaemia, both of which may compromise patient safety.
MicroEye delivers real-time blood glucose data which meets ISO 15197 accuracy criteria which results in improved patient outcomes, speedier recovery and shorter hospital stays.
Lactate Monitoring
MicroEye® can be used to assess metabolic stress by monitoring blood lactate levels. High blood lactate (hyperlactatemia) is frequently found in critically ill patients and often used as a marker of adverse outcome. A study* looking at all adult ICU admissions (n=13,932) in a healthcare institution over a three-year period found incidences of high blood lactate between 40 and 45 per cent. There was also a highly significant association between hyperlactatemia (blood lactate > 2 mmol/L) and mortality rates of 27 per cent. Other studies show that mortality rates of nearly 70 per cent are independently associated with blood lactate levels of at least 3.5 mmol/L.

MicroEye gives a reliable measure of cellular hypoxia and can help assess the effectiveness of therapeutic interventions. This data can then be used to improve patient outcomes and allow for a speedier recovery
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Cost saving benefit through better glucose monitoring which has been proven to  improve patient well being resulting in shorter hospital stays
  • Automated continuous monitoring freeing up nurses and other staff to perform other essential tasks, which improves efficiency and ultimately provides a cost saving benefit to the NHS
  • Published work shows an improvement in patient outcome and cost savings from continuous Glycaemic control
  • Trend data can be displayed rather than point in time
  • Compares favourably in cost to current methods.
  • Many other analytes can be collected at the same time and measured offline  e.g. antibiotics
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Our  innovation will bring benefits to patients using the technology as soon as it we have finalised trials and able to bring to market. Thus during this development and the final marketing of this product it will help us secure the growth and develmpent of the company as well as it products, current and futurre

We also are looking forward to developing collaborations and stronger relationships with West Midlands NHS Clinical reseach teams to enhance one anothers research and the care we can deliver to patients.

Some of the lactate research has been conducted at the University of Coventry
Current and planned activity: 
  • Seeking NHS Evaluation Centres / collaborators - We plan to commence evaluations in NHS centres, if possible here in the West Midlands
     
  • Gaining Evaluation and Validation - The device is in final evaluation stage, although it is CE marked for use in EU hospitals
     
  • Developing Final Products & Sales - Following this we will moving through to mass production and growing our sales base from our offices in Coventry and developing exports to countries that have been showing interest.
     
  • Note: To early to say ROI - Value or Time Scale but we suspect thes will be very favourable and beneficial to the NHS and patients.
What is the intellectual property status of your innovation?:
Patented product and IP held by company. Licenced out IP to be used to integrate with other products abroad (Japan and Italy).

Curent Certification:CE marked product, ISO 13485, Directive 93/42/EEC
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Regional Scalability:

We have already conducted feasability studies with our manufacturer to ensure volume production is possible

Measures:

Initially we are looking for user evaluations. We already know the device works succesfully. A full trial protocal is avilable in request

Adoption target:

initially we would lie to start eavuations in 1 -3 centres.

Read more
Hide details
Neil Smith 01/03/2016 - 14:03 Detailed Submission Login or Register to post comments
3.8
5
Votes
-99999
Innovation 'Elevator Pitch':
A medical screening technology based on a mathematical model of the autonomic nervous system & physiological systems which has significant potential to improve the cost-effectiveness of primary care
Overview of Innovation:
Strannik technology is based upon a mathematical model of the autonomic nervous system and physiological systems. It meets the key aims and objectives of the EC’s Human Brain Project: (i) to identify what the brain does and how it does it, (ii) to develop a new generation of cognitively-based screening technology, (iii) to understand and adapt with therapeutic effect the multi-level nature of brain function.  This is quite without precedent in modern medicine. The Strannik technology comprises Strannik Virtual Scanning (SVS) and Strannik Light Therapy (SLT). 
The technique can be viewed in a demonstration video at the following link: www.montaguehealthcare.co.uk/presentation.php
SVS is a screening technology which has an unprecedented ability to determine the health of the patient i.e. it is able to determine 5-15 pathologies in each of the 30 main organs (including medical conditions for which the current tests are poor or for which there is currently an unmet clinical need), to differentiate between and quantify the extent of the genotype and phenotype in each pathology, and to determine the earliest onset of each pathology from its presymptomatic origins. The technique adopts a methodology more advanced than is currently used in most diagnostic technologies. It is non-invasive and more safe than contemporary diagnostic tests. The results are available in circa 20 minutes at a cost which is estimated to be 5-10 times lower than contemporary diagnostic tests. It presents the opportunity to screen the entire UK population once (or twice) each year for less than £5BN (est £3-4BN) and to reduce the cost of healthcare by an estimated £20BN pa.
(See Operating Manual: www.montaguehealthcare.co.uk/OperatingManual.pdf)
The basic methodology, and the scope of this technology, is outlined in a series of 60 peer-reviewed medical papers.
(uk.linkedin.com/pub/graham-ewing/44/386/214)
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Strannik Virtual Scanning is able to determine all common pathologies in a single test of 20 minutes duration. In-market surveillance has indicated that SVS appears to be circa 2-23% more precise than contemporary methods of diagnosis. A recent non-clinical study in Spain (10/16) illustrated that the technology was able to determine all known medical conditions in the cohort of (20) patients.
 
Using the data derived from this cognitive, computer-based, test the technique determines the precise parameters of Strannik Light Therapy -which acts upon autonomic dysfunction, and (across a wide range of medical indications) appears to be typically 83-96% effective. This compares with the 50% effectiveness of drugs and also that the effectiveness of many drugs declines over a period.
 
Benefits:
 
  • reduce the flow of patients into the healthcare system;
  • reduce the cost and complexity of training the GP
  • improve the ability of the GP to identify complex medical conditions, reduce the need for repeat consultations, and/or avoid doctor errors
  • reduce the need for histopathology samples (nurses, rubber gloves, sampling tubes, transport costs, histopathology lab costs)
  • reduce expenditure in secondary care i.e. for highly expensive scans and tests;
  • provide health reports and increase the ability for patients to have a clear understanding of their health and assume responsibility for their health i.e. change the focus of medicine  from treating the symptoms to prevention
  • regularly screen the health of the most at-risk patients thereby reducing the need for A&E services
  • improve the accuracy of drug prescribing thereby avoiding mis-prescribing of drugs
  • reduce the need for drugs
  • reduce the overall cost of healthcare by an estimated £20BN pa
“I have to hand it to you. You have correctly and in precise detail identified the five or six major items which are known to be of concern to me”. Dr John Doran, Medical Director, Nottingham’s Queens Medical Center, November 2003.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Support patients to obtain an early diagnosis to seek timely treatment.
Current and planned activity: 
Mimix Montague Healthcare is actively seeking NHS partnerships to move forward Strannik Technology. Evaluation and trials have been conducted in other countries (Russia and Spain) and a collaboration within the UK is currently being sought.
 
  • Procurement / Adoption of Strannick Technology within NHS Trusts
  • Evaluation / Validation / Clinical Trial - Need to gain additional validation seeking a trial centre.
  • Project Assistance required - The Company’s development project is interested in locating possible clinical / academic collaborators.
What is the intellectual property status of your innovation?:
software/copyright
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
The technology is immediately scaleable. In theory, and as an indication of scaleability, we could train 1000 practitioners to use Strannik technology within 4 weeks. 
Measures:
Strannik Virtual Scanning is unique for a number of very good reasons e.g. (i) that it can determine pathological onset from its presymptomatic origins, (ii) it can determine the full spectrum of pathologies in all organs and not just a single biomarker, (iii) it can determine genotype and phenotype, and (iv) it can determine many conditions where there is currently an unmet clinical need.  Further studies are required to illustrate how such a sophisticated technology will complement the current range of biomarker tests which are generally used in clinical practice. The technique is non-invasive and has a base cost of circa £15/test thereby addressing safety and cost.  The procedure is entirely non-invasive which significantly enhances the patient experience, often experienced as 'a pleasure'.  
Strannik Light Therapy is based upon an understanding of how the brain regulates the autonomic nervous system.  A comparison of Strannik Light Therapy with contemporary methods of treating patients is likely to enhance the patient experience, result in significantly reduced side-effects, and will be at very much lower cost.
Success will be measured by reduced number of patient consultations, lower cost of diagnosing and treating patients. 
Adoption target:
Our aim is to secure the introduction of Strannik technology to every primary care practice
Rejection Reason:
Dear Mr Ewing Thank you very much for your submission to the Meridian Innovation Health Exchange. I can confirm that we have now reviewed your submission and i regret to inform you that we have not been able to identify any clinical champions for this project. While I appreciate that Strannick are looking for support on the evaluation/evidence side, feedback from clinical / academic colleagues has not been positive and therefore we have done everything possible to engage but the appetite isn't there unfortunately. Given that our network is not focussed in exploring this area at this time we will therefore close your idea leaving it visible to our Meridian users. We wish you luck with your innovation. Regards The Meridian Team
Read more
Hide details
Graham Ewing 22/03/2016 - 15:50 Rejected Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
e-ASPECTS automates medical imaging analysis, providing confident decisions in the treatment pathway for acute stroke patients.  e-ASPECTS automatically implements the clinical scoring methodology, Alberta Stroke Programme Early CT.
Overview of Innovation:
Brainomix’s ground-breaking technology, e-ASPECTS, circumnavigates the time lag to treatment by automatically implementing the Alberta Stroke Programme Early CT Score (ASPECTS) scoring system on brain images from acute ischemic stroke patients, to identify and quantify signs of early ischemic stroke damage and provide an assessment to support treatment decisions.

Innovation of Brainomix e-ASPECTS Stroke Imaging
The key thing to note that is that the solution is highly innovative and first to market of its kind with no comparable solution available. Our co-founders include Professor Alastair Buchan, dean of medicine at Oxford University and the inventor of the ASPECTS score, and practicing clinician Professor Iris Grunwald, interventional Neuroradiologist at Southend Hospital and one of the first physicians to be successfully performing thrombectomies in the UK. 
  • e-ASPECTS is a decision support tool that automates the clinically validates ASPECT method scoring of CT scans, providing a fast, standardized result
  • e-ASPECTS is the only decision support tool for scoring non-contrast CT scans of stroke patients using the ASPECT method - a well established stroke scoring system
  • It is CE marked and has been validated to perform as well as expert Neuroradiologists in performing ASPECTS on hyper-acute stroke patient scans
  • Multiple randomized multicentre clinical trials have demonstrated (as recently as last year) that endovascular treatment is effective, and it is set to become the future standard of stroke care (in conjunction with existing thrombolysis treatments).
  • International guidelines for the selection of patients for this treatment include the ASPECTS score for identifying ischaemic core on non-contrast CT scans
 Health Economics
·         Reduced length of stay – baseline 0.04 days per patient
·         Identifies the correct treatment option for stroke patients and speeds up
          treatment times
·         Reduced decision making time for stroke patient – baseline 15 minutes per
          patient
·         Increased uptake of thrombectomy - baseline x 1.1 (i.e. 10% increase)
·         Cost savings - projected cost saving for a 15 minute time reduction in
          decision making is £40 of consultant time, plus £21 from reduced length of
          stay, leading to a total of £61 saving per patient. If thrombolysis uptake is               also increased by 20%, the total saving rises to £150 per patient.


 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Digital health
Benefit to NHS:
Health Economics
·         Reduced length of stay – baseline 0.04 days per patient
·         Identifies the correct treatment option for stroke patients and speeds up treatment times
·         Reduced decision making time for stroke patient – baseline 15 minutes per patient
·         Increased uptake of thrombectomy - baseline x 1.1 (i.e. 10% increase)
·         Cost savings - projected cost saving for a 15 minute time reduction in decision making is £40 of consultant time,
          plus £21 from reduced length of stay, leading to a total of £61 saving per patient. If thrombolysis uptake is also
          increased by 20%, the total saving rises to £150 per patient.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Better patient outcomes and treatment options.
Current and planned activity: 
We already have a number of NHS Hospitals and hospitals abroad using this solution. Once we have engaged with a Clinician who is interested in this solution we arrange to provide them with a demonstration so they understand the full benefits of the technology.
What is the intellectual property status of your innovation?:
IP is wholly owned by Brainomix. We follow a "trade secret" approach rather than patenting as we believe that this is more appropriate as it is a software device.
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regulatory Approvals:
Please describe any current regulatory approvals you have achieved and how they were met/ in progress/planned.
Commercial information:
Please describe how the product/service is being developed commercially, whether in development, trials, pilot or full commercial delivery. Include the results you have from any market/demand surveys and forecasts . Please include any research you have on the broader commercial opportunity for the innovation both within the health sector nationally and internationally.
Investment activity:
Please describe what stage of investment you have reached and whether you are seeking additional rounds of investment. Please include cash investment as well as investment of soft assets such as access to specialist equipment, knowledge, trial base etc. and indicate the types/sources of your investment such as grants etc.
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Investment sought:
What investment are you looking for in order to support wider adoption of this innovation and what have you managed to secure to date? Please provide a breakdown of these costs if possible.
Read more
Hide details
Deb Whitehall 26/04/2016 - 17:26 Publish Login or Register to post comments
6
1
Votes
-99999
Initial Review Rating
3.93 (3 ratings)
Read more
Hide details
Anonymous 12/05/2016 - 11:36 Deleted 1 comment
Innovation 'Elevator Pitch':
The RAPID project is a pioneering research study using real-time diagnostic information inspired by the world of Formula 1.
Vital signs continuously monitored wirelessly and advanced algorithms provide early warinng of deterioration.
Overview of Innovation:
The RAPID (Real-Time Adaptive and Predictive Indicator of Deterioration) project – is the first of its type in the world. It constantly collects data from children on our cardiac wards including their:
  • heart rate
  • breathing rate
  • oxygen levels
This is a new and exciting way for children to be monitored and gives important early warning signs of deterioration that can be acted on quickly. 
The study was based on McLaren’s expertise in using hundreds of sensors to collect and analyse real-time data during a race to optimise its strategy on the track and Aston University's expertise in applied mathematics.
This technology has been adapted to be used in healthcare for the first time. Hi-tech wireless sensors, designed by Isansys Lifecare are attached to the chest and hands/ankle of children to measure vital signs. The information collected is processed in real-time using machine learning techniques developed by mathematicians from Aston University which are embedded into McLaren’s data analytics platform, LIFEINSIGHT™.
This new technology means that signs normally recorded every one to four hours on paper charts could potentially become a thing of the past. Children will have access to continuous individual monitoring that gives more accurate information helping them to receive faster treatment and shorter stays in hospital.
The wireless technology and wearable sensors remove the need for cables and leads, which can restrict effective monitoring. This means parents can hold and interact normally with their child while knowing they are being safely and continuously monitored.
The three-year study was jointly funded by a £1.8 million grant from the Welcome Trust and Department of Health, through the Health Innovation Challenge Fund, started in November 2014, and aims to recruit around 1,200 patients when it reaches its completion in late 2017.
 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Wireless monitoring is complex but worth solving for the future as it is definitely easier to have patients not wired up to expensive monitors. More patients can be monitored more frequenly at a reduced cost.
Advanced early warning will allow earlier detection and treatment of deterioration and therefore hopefully prevent the healthcare and human costs of preventable deterioration.
Initial Review Rating
4.60 (1 ratings)
Online Discussion Rating
5.50 (2 ratings)
Benefit to WM population:
There will be large numbers of recruits to this Portfolio adopted study. Scaling up planned in WM hospitals.
Current and planned activity: 
In feasibility trial phase to complete in November 2017 and report May 2018. Follow-on trial to be designed in 2016 looking at scaling up in BCH and other centres.
What is the intellectual property status of your innovation?:
Copyright of visualisations, trademark of logo and patent of algorithms in process.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
3
Read more
Hide details
Heather Duncan 13/05/2016 - 10:11 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Evaluation of near patient testing within community pharmacy to help reduce inappropriate antibiotic prescribing associated with respiratory and urinary tract infections.
Overview of Innovation:
Inappropriate antibiotic prescribing can lead to higher rates of antimicrobial resistance. Taking steps to reduce the number of inappropriate antibiotics prescribed will help delay the emergence of resistant organisms and prevent harm by reducing the incidents of Clostridium Difficile. 

GP practices are often the first port of call for infections such as such as sore throats. It is estimated that 50-95% of sore throats in adults and 70% in children are caused by respiratory viruses which could potentially be managed safely within community pharmacy without the need for antibiotics.

Patients presenting with sore throats to GP practices fall into three groups namely, those with clear bacterial infection, those with viral infection and those where there is a degree of diagnostic uncertainty. In the latter group, a near patient test to aid diagnosis may help reduce diagnostic uncertainty and may prevent inappropriate antibiotic prescribing. 

Near patient testing is well established in general practice e.g. urine test strips for urinary tract infections. Recently, other devices have been introduced which look at CRP, Strep A, RSV, Flu.  These devices have been shown to aid diagnosis rates. 

However, conducting near patient tests in GP practice does not help address the current workload and capacity issues experienced by GPs. It is therefore proposed that such tests could be conducted in the Community Pharmacy.

Patients with diagnostic uncertainty could be referred by the GP to their community pharmacist to have a diagnostic test and dependent upon the results have the most appropriate treatment dispensed. Community pharmacists could supply antibiotics in line with local formularies if the test results were positive or self advice / over the counter medicines if the results were negative. 

By developing and evaluating this care pathway, we aim to evaluate whether this helps reduce overall antibiotic prescribing in primary care. We would also evaluate patient satisfaction, the impact of GP workload as well as pharmacy satisfaction with near patient testing. 

Initially we would like to evaluate one device but this patient pathway could be applied to other near patient tests. If successful, ear patient tests could be incorporated in common ailment schemes whereby patients approach their "pharmacy first" rather than their GP practice for sore throats or urinary tract infections. This would help reduce demand on GP services.  



 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Patient and medicines safety / Person centred care
Benefit to NHS:
The NHS would benefit on a number of fronts. 

1. Reduce inappropriate antibiotic volume. This will help delay the emergence of of antimicrobial resistance which in turn help prevent incidents of C Difficile and related multi-resistant infections in the future. 

2. A reduction of unplanned admissions associated with C Diff will help reduce pressure of the acute sector. Similarly, any reduction in hospital admissions will help the NHS save money. 

3. Introduction of a new care pathway involving near patient testing within community pharmacy will help reduce workload pressure on GP practices. A recent survey of GP surgeries has shown that GP waiting times have increased from an average of 9 days in April 2014  to 13 days in APril 2015. Near patient tests can take from a couple of minutes to 10 minutes. By doing these tests during a  GP consultation will add time which could be potentially be avoided if done elsewhere.

4. New ways of working between GPs and community pharmacists are part of the Five Year Forward View. A clear and robust pathway will help utilise existing capacity in community pharmacy to support other primary acre contractors such as GPs. This also strengths the links between community pharmacy and GP practices and will foster closer working between the two primary care contractors. 


 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Manir Hussain 20/05/2016 - 17:18 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
FebriDx® is a rapid, point of care test that uses a capillary blood sample to help identify a clinically significant immune response to acute respiratory infection and differentiate viral from bacterial aetiology.
 
Overview of Innovation:
FebriDx detects elevated levels of Myxovirus resistance A (MxA) –
an intracellular protein that becomes elevated in the presence of acute viral infection
and C-reactive protein (CRP) – an acute-phase inflammatory protein that is elevated
in the presence of bacterial infection.

•    Accurate results eliminate diagnostic uncertainty.
•    Enables GPs to make targeted and informed therapeutic decisions.
•    Supports patient discussion around the clinical pathway of viral infection.
•    Reduces unnecessary prescriptions of antibiotics.
•    Optimises costs associated with clinical management of acute respiratory infection.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Innovation and adoption / Patient and medicines safety / Person centred care
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Laura Daniels 06/06/2016 - 16:52 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Development of a portable device that will rapidly and accurately determine whether an NG tube has been correctly placed into the stomach.
Overview of Innovation:
Many patients in hospital are unable to swallow safely, and therefore need to be fed by an NG tube passed down their nose into their stomach. Before any liquids can be given to the patient down the tube, it is essential that it is proven to be in the stomach. If it is not in the stomach, there is a danger that the food or drugs given will be delivered into the lungs, which is highly dangerous and completely unacceptable.
 
The normal way of confirming that the tube is correctly placed is for a small amount of gastric acid to be aspirated up the tube, and the pH confirmed to be <5.5. This should be done each and every time before the tube is used – this may be many times in a 24-hour period.
 
Approximately one third of the time, it is not possible to confirm correct tube placement this way – either acid cannot be aspirated, or the pH is >5.5. In these cases, an Xray is required to confirm tube placement. This leads to delays in the tube being used for essential nutrition / drugs, to disruption to the patient experience, to additional radiation, and to additional use of other hospital resources (eg portering the patient to Xray).

We are currently working with Warwick University to build a portable analyser to put into a hospital. We have designed a pilot study to evaluate the scientific method we have developed, which has received ethical approval. If the results are favourable, we envisage a larger trial in multiple centres.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
If the research confirms what we expect then it is expected that an analyser could be made available to hospitals to allow a highly accurate and rapid bedside test of NG tube placement. This would have a number of likely impacts:
  • Reduction in the risk of Never Events
  • Reduction in the need for X-rays
  • Reduction in the amount of time that NG tubes are not used while their position is being checked. Therefore, patients will experience less interruptions in their nutrition and medication, and the associated medical complications which could have arisen as a result.
  • A probable reduction in length of stay of patients
  • Reduced costs to the Trust (and the wider NHS), for all the reasons outlined above
  • Commercial opportunity to patent the technique, manufacture the gas analyser, etc
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
If the research confirms what we expect then it is expected that an analyser could be made available to hospitals to allow a highly accurate and rapid bedside test of NG tube placement. This would have a number of likely impacts:
  • Reduction in the risk of Never Events
  • Reduction in the need for X-rays
  • Reduction in the amount of time that NG tubes are not used while their position is being checked. Therefore, patients will experience less interruptions in their nutrition and medication, and the associated medical complications which could have arisen as a result.
  • A probable reduction in length of stay of patients
  • Reduced costs to the Trust (and the wider NHS), for all the reasons outlined above
  • Commercial opportunity to patent the technique, manufacture the gas analyser, etc
Current and planned activity: 
A study has been designed by the the nutrition team and UHCW, in collaboration with the School of Engineering at Warwick University. This has been granted ethical approval, and will be completed by the end of Aug 16.
 
  • Study design – observational cohort study
  • Study population – patients at UHCW NHS Trust with NG tubes already in place – based on predetermined clinical decision.
  • Intervention
  • Outcome Measures – the results will be compared to the current method.
If anybody wishes to discuss this with us we would be interested in arranging for a confidentiality agreement to be put in place to allow conversations.
What is the intellectual property status of your innovation?:
No formal protection in place as of yet though will be sought after the trial stage. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Regional Scalability:
In development 
Measures:
In development 
Adoption target:
In development 
Read more
Hide details
Richard King 18/07/2016 - 10:10 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
LiverMultiScan is an FDA 510(k) cleared and CE marked MRI technology that provides a quantitative assessment of liver health, including fibroinflammatory disease, steatosis and iron, all in a non-contrast 5 minute scan.
Overview of Innovation:
Perspectum Diagnostics is a medical imaging company with an ISO 13485 compliant CoreLab. The company has developed novel imaging technology, LiverMultiScan, an MRI-based non-invasive tool that has attained CE-marking and FDA 510(k) clearance to aid the diagnosis of patients with chronic liver disease.
LiverMultiScan (and LiverMultiScan Discover for clinical trial use) can characterise liver tissue in three ways, providing accurate measurements of liver fat, hepatic iron content and fibro-inflammatory disease, using the proprietary Liver Inflammation and Fibrosis (LIF) score. The LIF score has been shown to stratify NAFLD and NASH patients (Pavlides, 2015), correlate with histological markers of inflammation and fibrosis (Banerjee, 2014), and most importantly, is the first imaging test to predict liver-related clinical outcomes (Pavlides, 2016). It is the only liver imaging technology included in the UK Biobank study, with 100,000 scans to be performed in the coming years (Kelly, 2015).
Available as a Quantitative Analysis Service (QAS), LiverMultiScan has been cleared as an imaging tool to aid the diagnosis of early liver disease. It offers a standardised and high-quality method for supporting Gastroenterology/Hepatology and Radiology departments in diagnosis and monitoring of the liver in clinical settings and studies, and has potential to streamline clinical management by compressing the diagnostic pathway. Perspectum is also supporting multiple international clinical trials with LiverMultiScan Discover.
  • Banerjee et al. (2014) Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 60:69-77.
  • Kelly et al. (2015) Predicted prevalence of NAFLD and NASH in a large population using non-invasive multiparametric MRI. AASLD 2015. Abstract ID: 931.
  • Pavlides et al. (2015) Multi-parametric magnetic resonance can accurately assess NAFLD histological disease severity; comparison with transient elastography. AASLD 2015. Abstract ID: 2190.
  • Pavlides et al. (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol. 64:308-315.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Patient and medicines safety
Benefit to NHS:
The utility of LiverMultiScan for assessing fibroinflammatory disease, steatosis and predicting clinical outcomes means it is well-positioned to reduce (and potentially remove) the need to perform invasive liver biopsies. It also facilitates longitudinal monitoring, which is near impossible with current sampling technology.
According to a recent NIHR HTA report, the cost of a liver biopsy is £956, but this can increase significantly with complications (clinically significant bleeding in 1.1 – 1.6%). For healthcare providers, liver biopsies are unappealing because of the attendant risk, financial cost, lack of reliability (as sampling only 0.002% of the liver volume), and uncertainty in interpretation. Nevertheless, primarily because there has not been a viable alternative, it is estimated that 650,000 liver biopsies are performed annually worldwide. 
There are substantial costs associated with managing patients with NAFLD, in particular for those patients progressing to NASH who are at significant risk of cirrhosis, HCC and liver failure. Although pharmacologic options are limited, there are numerous clinical trials ongoing.
Available treatment options increase (e.g., diet, surgery), outcomes improve and healthcare costs decrease the earlier those with, or at risk of, more advanced disease are identified. When combined with the rising incidence of NAFLD and NASH, the availability of a non-invasive test for accurately assessing fibroinflammatory disease, steatosis and predicting clinical outcomes, is vital.
A recent health economic study (submitted for publication) from the University of Birmingham concluded that LiverMultiScan is cost effective either as an adjunct to or replacement of Fibroscan in the diagnostic pathway of NAFLD. In addition, the utility of LiverMultiScan in reducing the proportion of patients with suspected NAFLD undergoing hospital consultations and/or liver biopsies is currently being evaluated in a large Europe-wide multicentre clinical trial (including the UK).
LiverMultiScan could allow:
  • A faster throughput and diagnostic analysis than conventional sampling – reducing patient lists and identifying those that need and do not need clinical intervention.
  • Regular monitoring of patients without painful invasive and potentially dangerous biopsies.
  • A less traumatic assessment of liver disease in children.
  • Assessment of liver health in other diseases (e.g., viral hepatitis, alcoholic liver disease)
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
Liver disease is the fifth ‘big killer’ in England and Wales, after heart, cancer, stroke and respiratory disease (http://www.britishlivertrust.org.uk/about-us/media-centre/facts-about-liver-disease), with twice as many people dying from liver disease now compared to 1991.
In a European study, the healthcare costs for patients with NAFLD were 26% higher than for those without the disease (Baumeister, 2008). In the US, the direct costs of cirrhosis and chronic liver disease were estimated to by $2.5 billion, whereas indirect costs were estimated to be $10.6 billion (Ruhl, 2008).
Identifying those with, or at risk of, more advanced liver disease earlier increases treatment options available, reduces healthcare costs and improves outcomes. Benefitting both the NHS and wider West Midlands community.
This diagnostic test could also be used to aid the diagnosis and monitoring of liver disease in children, with a European clinical trial underway.
 
  • Baumeister et al. (2008) Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology. 134:85.
  • Ruhl et al. (2008) Costs of digestive disease. In The Burden of Digestive Disease in the United States. NIH Publication. pp 137-143.
Current and planned activity: 
LiverMultiScan currently in use at University Hospitals in Birmingham, Edinburgh, Oxford Southampton & Kings College London (KCL). Discussions with other NHS sites

Recent completion of large Innovate UK funded 2.5 year study at University Hospitals Birmingham & Edinburgh to develop & validate against liver biopsy

KCL is UK site for large EU multi-centre clinical trial to evaluate cost-effectiveness of LiverMultiScan in primary care pathway.

Patient study - 100 patients with history of liver disease receive LiverMultiScan, nearing completion with extremely +ve feedback

LiverMultiScan is only liver imaging technology in UK Biobank - 100,000 subjects to be imaged

Planned activity
West Midlands location of choice as:
  • Build on relationship with University of Birmingham following 2.5 yr study
  • West Midland’s considerable expertise in liver disease
  • Large patient cohort and trials infrastructure
  • Involve Children’s Hospital in study
  • Dr Banerjee, founder & CEO, visiting Hon. Consultant Hepatologist at UHB
What is the intellectual property status of your innovation?:
Perspectum holds or exclusively licenses 7 patent applications in the UK and other territories. To date, one has been granted in the UK (GB2497668).
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Matt Kelly 03/08/2016 - 11:07 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Disruptive technology prevents Left Ventricular remodelling post MI & promotes tissue regeneration. Product result of £10M EU investment & 5 years R&D. Biocompatible & Biodegradable product demonstrated pre-clinically in wide range of animal model.
Overview of Innovation:
Cardiac patch is a scaffold structure compatible with in-vitro cell seeding & cell culture used as a vector for cellular therapy in addition to structural support. Numerous applications include curettage & cardiac transmural use in addition to soft tissue engineering such as hernias & vein repair. Scaffold composition comprises poly(caprolactone), alginate & composites thereof with natural polymers such as chitosan & alginate fibroin decorated with a synthetic peptidic hydrogel. Porosity can be tailored with pore range of 10-250µm, permitting angiogenesis and cell seeding. Although the biomaterial can be used independently as a medical device for prosthetic applications, its main tissue engineering function is to enhance cell attachment, growth & differentiation. An extension of the device is its functionalisation with cell signalling agent capacity providing the scaffold with extracellular matrix like micro-environment. Polymeric self-assembled structure is composed of but not limited to peptidic or polyurethane amphiphiles & can be loaded with chemical & biological cues covalently or via entrapment.

To initiate regeneration, the biomaterial must encourage in-vivo revascularisation & promote integration with host tissue. Concurrently, it should biodegrade at the same rate that newly formed tissue replaces it, being removed from the body by natural metabolic pathways without toxic by-products.

The patch provides both a temporary mechanical support to the infarcted myocardium preventing further damage to the surrounding tissue and prevents aneurism formation in the infarcted area whilst regeneration take place

Myocardial infarct treatment
Device can be used for in-vitro & in-vivo applications. Both parts of the device can be loaded with cell signalling agents or drugs for research & clinical use. Fibre based secondary drug delivery structure allows multiple growth factor/drug release with different release profiles as a direct tool for gel functionalisation with patient blood components in-vivo.

The system’s mechanical properties match the tissue it replaces. 3D hydrophobic/hydrophilic scaffold provides mechanical support to a gel that acts as scaffold plasticizer & provides an hydrophilic interface with host environment. The gel can also collect cell signalling agents from its immediate environment. The electrospun fibre based drug delivery system can additionally be used as a complementary tool to the gel for loading with cell signalling agents, drugs etc
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
The leading global trend in interventional cardiology is to adopt less invasive technologies, reducing patient recovery time & improving quality of life.
 
PeptiGelDesign Cardiac Patch treats myocardial infarction (MI). Current treatments are based on medication &/or organ transplantation. Approx. 4,600 heart transplants are carried out pa in Europe & the USA (1,900 EU). Even with current medical management, over 1/3 of acute heart attacks are fatal. Rehabilitation levels following MI are variable with major damage unable to be fully healed. Current treatments to prevent tissue damage post MI include thrombolytic agents. These drugs have greatly reduced morbidity & mortality, but must be administered within a short interval following MI to be effective. Cardiac catheterization & Angioplasty have proven effective in restoring blood flow, but cannot reverse tissue damage. Transplantation is complicated surgery, severely limited by lack of donor organs.


Advantages of cardiac patch over current treatment regimes:
 
• Complements established therapies restoring damaged cardiac muscle ensuring improved contractility function & eliminating CHD related early mortality. Following non-lethal MI current treatments effectively restore blood flow, but cannot reverse tissue damage leading to limited rehabilitation & QoL
 
• Restoration of cardiac function drastically reduces re-infarction rates & need for subsequent interventions.


• Demonstrably increases life expectancy post MI. In cases of CABG (bypass), 5-year mortality rate for target population (patients with abnormal Left Ventricular (LV) function typically caused by MI) is 16.5% vs a mortality rate for patients with normal LV function of 8.5% (50% improvement). We could expect the cardiac patch to reduce mortality of patients undergoing MI to the level of those with normal LV function due to recovery of infarcted heart. Similarly, 5-year mortality rate of 80% for post MI patients undergoing an interventional procedure decreases to 40% - the mortality rate for patients undergoing the same procedure but with normal LV function.


• By enabling recovery of the heart muscle patients improve their NYHA class, suffer less Angina Pectoris, reduced incidence  of re-infarction, need less medication & hospitalization & improve QoL. NB: 10 years post CABG intervention, overall survival rate is 69% vs overall event free rate of 41%, suggesting that a significant portion of patients are surviving but with a fairly low QoL
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
In addition to the many benefits to the wider NHS outlined above, there are specific regional benefits accruing from the adoption of this medical device and treatment regime.
 
The high incidence of Chronic Heart Disease and the costly rehabilitation of patients post heart attack is a recognised priority within the West Midlands population.
 
The cardiac patch offers a minimally invasive and rapidly deployable intervention that will significantly improve the quality of life for patients surviving Myocardial Infarction.
 
In addition, the cost and time savings to the NHS and social care through improving patient outcomes, reduced number of transplants and greater quality of life and increased independence for patients post MI will be significant.
Current and planned activity: 
(See attached document for more information)
PeptiGelDesign is currently engaged with the Liverpool Heart and Chest Hospital.

Wish to partner with NHS and NHS Research Organisations on clinical trials for cardiac patch development.

As our primary target market is the UK, we wish to raise profile within the NHS and work with its stakeholders to bring our technology to the market and ultimately to the patient.
  • Explore if entitled to an  Investigational Device Exemption (IDE) ?
  • Identify sources of funding to support PeptiGelDesign pursuing the further validation.
  • Procurement/Adoption: -  Require routes to GP sales - marketing products to CCGs
  • Evaluation/Validation/Clinical Trial - Need to gain additional validation - seeking a trial centre.
  • Concept Development - This is planned development work but seeking NHS partnership/advice.
Project Assistance required - The Company is interested in locating clinical/academic collaborators for new product development.
What is the intellectual property status of your innovation?:
PeptiGelDesign Ltd is licencing the WO2014044321 and finance patent granting process. Today, the patent has been accepted in USA, EU and Japan and will enter EU countries national phase in December 2016.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Guillaume Saint-Pierre 04/08/2016 - 09:33 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
A community based pathway to detect asymptomatic chronic liver disease at a critical stage at which it can be halted or reversed. At risk patients are proactively identified and the use of a non-invasive diagnostic test (Fibroscan®) is utilised.
Overview of Innovation:
Liver disease constitutes the third commonest cause of premature death in the UK (ONS 2010) and the death rate is continuing to rise (Williams et al 2014). This is despite the fact that the majority of liver disease results from lifestyle related risk factors including excess alcohol use, obesity (and related type 2 diabetes) and intravenous drug use. Liver disease develops over several decades due to a persistent insult causing low grade cellular injury and inflammation, resulting in the gradual development of advanced liver scarring and subsequently irreversible cirrhosis. Therefore, if the disease is detected early there are opportunities to reverse or halt this process.

However, current strategies to identify liver disease within the community are inadequate resulting in approximately 50% of patients with cirrhosis being diagnosed when they present to hospital with end-stage liver disease where subsequent prognosis is poor (Ratib et al 2014). In primary care, liver function tests (LFTs) are the main diagnostic test used to identify patients but these are inadequate. Many patients with elevated liver enzymes have no significant evidence of disease, and normal LFTs do not rule out the possibility of cirrhosis. However, there is the potential to use newer non-invasive tests to detect early stages of liver disease by targeting those patients with established risk factors.

NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospitals Trust and local GPs have collaborated on a pilot study within four suburban GP practices.  This study evaluated the feasibility of implementing a new diagnotic pathway and using a new non-invasive imaging test called a Fibroscan, to detect liver disease within the adult community.

Out of a patient population of 20,368 adult patients, 2,022 were identified to be at risk due to hazardous alcohol use or having a diagnosis of type 2 diabetes. Nine hundred and nineteen patients accepted an invitation to attend their GP practice for a Fibroscan. A significant proportion of patients who had a Fibroscan have liver scan results compatible with liver scarring (25.6%) and 26 new cases of cirrhosis were identified. Importantly, 68.3% of the patients with an abnormal Fibroscan, and 73.1% of patients diagnosed with cirrhosis, had normal LFTs and would not have been detected through normal standard of care.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Innovation and adoption
Benefit to NHS:
Integrate primary and secondary care to provide an effective and specialist service within a community setting.
Increase knowledge and awareness of liver disease in primary health care teams and within the general public.
Create an economic model to provide financial information about the long term cost effectiveness of the pathway. The pathway costs are also significantly within the NICE threshold of £20,000 per quality-adjusted life-year (QALY) at £2,138 per QALY for NAFDL and £6,537 per QALY for ALD
The pathway is picking up patients much earlier, with the ultimate aim of halting the condition or dramatically improving patient outcomes compared with current processes which often lead to patients not being identified soon enough.
It has undergone a full health economics evaluation and attracted interest from regional Clinical Commissioning Groups (CCGs) which has recently included the team facilitating the redesign of the liver disease pathway in one locality.
Benefit to WM population:
Promote the Scarred Liver project diagnostic pathway to other East Midlands CCGs and support the development of further commissioning cases where possible.
Adoption
There are 12,000,000 people nationally at risk – the pathway will identify these people if scaled throughout England and Wales. We would like to establish a roadmap to expanding the pathway from a regional to national service
1. Adoption and diffusion of innovation and research
2. Spreading best practice
Current and planned activity: 
Engage with commissioners and providers to facilitate the implementation of the pathway into multiple areas within the East Midlands.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Rebecca Harris 05/08/2016 - 15:32 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
BVI technology is an innovative and easy to use, mHealth service to determine the percentage and distribution of visceral fat using a mobile device (tablet) or a smart phone. 
Overview of Innovation:
The Body Volume Indicator (BVI) is a new measurement for healthcare and obesity. After eight years of successful and innovative validation from scientific collaborators around the world, BVI is now undergoing final testing prior to a full launch later in 2017.

Using 3D technology, BVI calculates risk factors associated with a person's body shape, by measuring weight and body fat distribution, with particular focus on the abdomen; the area associated with the greatest risk.

BVI is designed to be a long-term addition to the Body Mass Index (BMI); the current recognised standard for measurement of obesity. The intention is for the Body Volume Indicator to become a Body Volume Index by 2020, by which time sufficient data will have been collected globally. Using smartphone technology, BVI data can now be collected anywhere with web or internet access.

Body Volume, as an indicator of health, offers a potential long-term solution as a measure of individual health risk. 

BVI was developed in the West Midlands and collaborators have included Heartlands Hospital, Aston University, Mayo Clinic and the Medical Research Council. The application was patented in the US in 2012 and throughout Europe in 2015.


 
Current Status
In 2012 Select Research obtained exclusive use of the largest and most comprehensive collection of Body Composition Data (BCD) of visceral fat data from MRI scans in the world. This has been used to develop an App which will be used to scan/photograph lightly clothed patients and then comparing their BCD database to predict their body fat and visceral fat.
 
Further research and development is being undertaken with our current BVI (Body Volume Index) tool, to provide additional evidence and to validate the efficacy, and appropriateness of this BVI application in real-life environments. Through a ‘real-life’ project work with WMAHSN will provide clinical validation for the underpinning methodology, thus making potential users (Clinicians, patients & public) aware of the benefits (social and economic) of utilising the service.
 
Thus our current BVI application is to be incorporated into the existing patient pathways currently used by Health Exchange Health Trainers in the West Midlands.
 
NB: The application has been patented in the US in 2012 and throughout Europe in 2015 and covers all measurements of part body volume for healthcare from a 3D scan. Body fat is a part volume of the human body.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Visceral fat is body fat stored within the abdominal cavity around a number of important internal organs such as the liver, pancreas, and intestines often referred to as 'active fat'. This type of fat plays a potentially dangerous role in affecting how our hormones function.

Higher amounts of visceral fat are associated with increased risks of a number of health problems.  NHS healthcare costs attributed to obesity are £5.1b p.a. and set to rise by £7.1b by 2030; The cost to the UK economy is £27b p.a. Benefits through effective intervention based on accurate visceral body fat determinations are complex but undoubtedly would lead to a reduction in the burden of obesity (diabetes, heart disease, stroke, and certain cancers), by a reduction in years lost to premature mortality and disability (DALY). NICE suggests reducing obesity of 1% would save the “NHS and local authorities around £97 million per year.” Diabetes costs the NHS over £1.5m an hour or 10% of the NHS budget for England and Wales. 

The lifetime benefits of weight loss - direct £297 and indirect £2068 estimates based on 50% compliance and 25% success.  A saving to the NHS of between £1.2m and £6.9m, and the economy of between £135m and £1620m.

Select’s BVI tool App predicts the early identification body and visceral fat & estimates via a quick, simple and non-invasive scan which provides an insight and benchmark for clinicians and their patients; just by taking two photographs of a patient. 

Therefore BVI significantly contributes to the monitoring, intervention and control processes for clinicians and other health professional to apply, so that they can tackle and halt the potential for escalation into Diabetes and CHD etc.


Particular value for patients will be that they can monitor their own progress and to improvement at home. Through recognition of the scale of their own obesity and particularly any high levels of visceral fat. The early identification of visceral fat, through this simple, quick and accurate method of measuring obesity will thus take a large step towards achieving considerable saving to the NHS and the UK economy.

The proposal for delivery of BVI is under discussion with BVI data (including BMI, Waist Circumference, and Waist to Hip Ratio automatically) stored for tracking purposes on patient records via the N3 spine. Automatic data collection through BVI of current methods saves time, money and provides new informative data on body composition for future research.
Online Discussion Rating
5.50 (2 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Clinical Outcomes & Economic
In the West Midlands 65.7 per cent of people are carrying excess weight, along with 65.6 per cent of people in the East Midlands. Obesity costs the UK economy exceed £3 billion per year. In Birmingham, over 25% of the population are obese - the third highest rate in the UK. The high prevalence of obesity in adults within England show that national averages of over 40% of males overweight and more than 20% obese in the 16-75 year age range, while in women the averages are lower for the overweight classification but higher for obesity.
 
Nationally GPs make 97,000 annual referrals to weight watching programmes (WWP) and costs will reach £15.6m p.a. in 2017. A saving of £48.5 per patient might be made using the BVI App. With as low as 10% uptake, £0.5m could be saved, rising to £2.8m with a 60% uptake. Better management of weight issues with patients will have significant cost savings within the West Midlands.
 
This tool will support early detection of visceral fat and therefore allow a much more preventative and timely approach to supporting West Midlands Patients to make positive lifestyle change.
 
Environmental
The BVI App offers considerable environmental benefits in reducing the number of visits (road trips) to a surgery and specialist clinics. It will also allow people within remote and rural locations to engage in such activities.
 
Research
Additional R&D is being undertaken with the WMAHSN, to further ‘validate’ the efficacy, appropriateness and validity of the BVI application in real-life environments using the BVI App, which is being incorporated into the existing patient pathways.
 
Commercially
The adoption of this technology within the West Midlands and UK will also allow our company to grow and develop, not only with increasing its functions and capabilities but also in marketing this to a worldwide healthcare organisations and individuals as obesity is a major developed countries epidemic. 
 
There is also interest from other commercial organisations involved in weight management and associated healthcare which will further extent this products role and integration with people taking charge of their well being.

Trials
The BVI tool will be tested in 3 locations in the West Midlands with patients and GP Practices in Birmingham, Dudley and Solihull. Analysis of weight loss achieved over a period will be monitored.

Please assist us with our 5 min Survey http://BVISurvey.SSIsurveys.com​ 
Current and planned activity: 
Current BVI application is undergoing R&D and incorporation into existing patient pathways within the West Midlands via;
  • Patient Engagement - Face to face consultation, scanning of approximately 1000+ patients
  • Clinical Benefits - Analysis and monitoring of weight loss achieved over a defined period. Developing delivery protocols
  • Dissemination - Facilitation of BVI tool awareness raising sessions with Key Public Health and NHS Management, Clinical Teams and frontline staff
  • Training - BVI tool training to specialist clinical teams (Primary & Acute), ensuring correct use of the tool and providing feedback for use with patients
  • Data analysis – Verification/validation of App algorithms
  • Data gathering - Provision of clinically requested data – Core data profiling to gauge health outcomes and patient benefits. Establishing minimum data requirements
Required
  • Evaluation & Trials - Seeking trial interests
  • Adoption – Looking for discussions with CCG’s, Healthcare and Council Health Prevention teams   
What is the intellectual property status of your innovation?:
BVI has both BVI Patents and Trademarks approved.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
We have not as yet implemented at scale within the WM region or elsewhere. The BVI product will be launched in the US market in March 2017 and Select Research Ltd are currently in discussions with Health Exchange and NHS Heartlands Hospital (who are collaborators on BVI development) for a possible follow on wider trial across the region for 2017.
Measures:
When the BVI app has been fully completed in terms of it’s scalability for widespread use, the trial results have been published and the launch takes place in April 2017, the success criteria will be determined by the number of users and the take up when the product is available and being used by customers.
 
Development is currently ongoing with scaling of the technical infrastructure for release on all accepted and recognised technical platforms (e.g. Google Play. App Store) in late April 2017. The success criteria will then become easily measurable by virtue of the volume of downloads achieved after launch.
Adoption target:
These will be dependent upon the outcome of the discussions with NHS Heartlands Hospital and Health Exchange as to a future extended trial.
Read more
Hide details
Richard Barnes 16/08/2016 - 12:59 Approved Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':

The Recipe for Workforce Planning is an easy-to-use online tool driven by a dynamic process map.The Recipe is a repository for best practice and facilitates peer support through a discussion forum.

Overview of Innovation:

The Recipe for Workforce Planning is an easy-to-use online tool driven by a dynamic process map; users click on each stage of the process to access resources and view the activities needed to complete that stage. The Recipe is a repository for best practice and facilitates peer support through a discussion forum.

This unique resource is the first of its kind, developed by Health Education England working across the West Midlands, and is being shared for use across Health Education England.

The Recipe process map, created in collaboration with workforce planners across the West Midlands, shows the stages that should be completed in order to create a good workforce plan:
 
Users can click on a stage to open a Stage Page showing:

  • Ingredients - documents and resources needed to complete that stage which users can download.
  • Method - activities necessary to complete that stage with assigned roles.
  • Hints and Tips – any useful advice or intelligence that will support the completion of the stage

The Recipe also includes:
 
What should I be cooking this month?
Each stage in the Recipe has a date range during which that activity should be completed.  Users will be able to see the stages within the Recipe which are currently ‘active’ at the time they visit the site.
 
Roles and Responsibilities
Each of the activities within a stage has an assigned role e.g. Workforce Planner, Finance Lead.  Users will be able to sort and filter the site to view only the stages and activities relevant to their role.
 
Discussion forum
The Recipe has a discussion area where planners can share ideas and ask questions or queries.  
 
Cookbooks
Users can select their favourite resources from the site (Word, Excel, PDF documents) and download these into a pack, or Cookbook.  There are also readymade Cookbooks for particular users and scenarios e.g. Workforce Planning for Beginners, Meeting with the Executive Team, Workforce Planning for Commissioners.
 
Links and Resources
The resources – or Ingredients – available to users for each stage are added to and updated as new resources become available.  However, there may be useful resources, reports, articles or links that are not relevant to a particular stage but may be of interest to workforce planners.  These are available on the Links and Resources page that will include an archive of all the resources on the site.
 
The Recipe also includes a search function and an interactive glossary. 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Education, training and future workforce / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:

Provides an easy-to-use online tool driven by a dynamic process map, demonstrating what good workforce planning looks like. This unique resource is the first of its kind and can be used in any clinical or non clinical setting when looking to effectively workforce plan.

Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:

Provides an easy-to-use online tool driven by a dynamic process map, demonstrating what good workforce planning looks like. This unique resource is the first of its kind and can be used in any clinical or non clinical setting when looking to effectively workforce plan. This resource was developed by the West Midlands and includes templates and resources which are currently being used across the region.

Current and planned activity: 

We have launched this resource nationally and are actively promoting this resource across the West Midlands, incorporating any feedback we receive.

For more information or to access the Recipe for Workforce Planning click here

What is the intellectual property status of your innovation?:

Health Education England.

Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Sarah Chamberlain 25/10/2016 - 10:44 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':

Converting Clinical lab based Xanthochromia procedure into Near Patient testing/Point of Care Procedure using pocket sized spectrometer.

Overview of Innovation:

I am thinking of converting Xanthochromia lab based spectrophotometry procedure (SAH/fatal accidents/Head injuries) into Point-of-care/Near patient testing (POCT) procedure. A small pocket sized spectrometer is going to come soon in the market.

The device is a molecular sensor with cloud based database. The company offers developmental tools to build the database, by scanning  every material that exists in this world..from paracetamol to material science. 

Converting this to POCT offer some advantages: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses themselves without much technical comptency can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:

Converting this to POCT offer some advantage: The patient's sample need not travel long from A/E to Lab. AE consultants/Nurses can perform the procedure with ease and early intervention/timely diagnosis is made possible: facilitating quicker clinical decisions, reduce length of stay..improve morbidity and mortality. The Challenge ahead is converting this device into a FIT FOR PURPOSE medical diagnostic POCT device.

Current and planned activity: 

Contacted the chief technology officer of the Company (Consumer physics) awaiting response for modifying the device into POCT medical diagnostic device. If green signal given may discuss with NHS trust and start the joint development/clinical trial/evaluation/validation/verification using NHS trust as base 

What is the intellectual property status of your innovation?:

N/A

Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
GANAESH 27/10/2016 - 02:21 Publish 1 comment
4
1
Votes
-99999
Innovation 'Elevator Pitch':
A functional, digital, patient-centric, diabetes self-test system providing: self-care; patient-professional shared decisions; proactive interventions; complications prevention; data integration pan NHS provider; multi-faceted NHS costs savings.
Overview of Innovation:
awergq3wrg3w
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
wefefgvw
Benefit to WM population:
f23ef2e
Current and planned activity: 
23rwefw
What is the intellectual property status of your innovation?:
fwergq3r5g
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Baldev 31/10/2016 - 13:26 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
65m urine specimens analysed annually in the UK breaks down to 250,000 every working day, of which 45,000 will be unreliable. This means 45,000 patients daily who will not be treated for urine-based infections. Peezy Midstream means they can.
Overview of Innovation:
Peezy Midstream can save the NHS £30m in reduced retesting of the most common diagnostic procedure.

It is a simple but innovative device that automatically captures clean-catch urine from men, women and children (from toddler age). It is especially valuable for the elderly and pregnant women for whom accurate urine screening is essential.

The average national mixed growth rate reaches from 0.38% to over 70%; the average is 18% - that's nearly 1 in 5 patients who will not receive accurate right-first-time treatment from their urine specimen.

Peezy Midstream reduces mixed growth rates to 1.5%, which means many more patients will be treated right-first-time, saving the NHS as a whole over £30m in direct retest costs and over £1bn indirectly through saving repeat staff and resource time.

Peezy Midstream captures urine specimens hygienically - it prevents spills and splashing, improving infection control in healthcare settings. It can be held by the tube if help needs to be given - the assistant does not risk becoming soiled either.

Dignity is implicit; easy Peezy is comfortable, quick and removes the need to start-stop-start when giving a midstream urine specimen.

There is no down-side to using Peezy Midstream. It saves lives, saves time and money and reduces unnecessary broad spectrum anitbiotic prescribing. Peezy is poised to make novel cancer urine tests more efficient too.

Each Peezy kit costs just 87p on the NHSSC; use ten for every retest. Available on the NHS Supply Chain and on the UK Drug Tariff - growing in popularity with midwives and care givers to the elderly.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Peezy Midstream delivers huge cost and efficiency savings plus clinical benefits:

(See attached WM mixed growth data and separate cost savings model)
  • Reduction of average West Midlands mixed growth rate of 17.5% to 1.5%
  • West Midlands direct savings of £307,798
  • West Midlands indirect savings of £12,339,337 (see attached WM cost savings model)
  • reduced urine specimen mixed growth from West Midlands average  to 1.5%
  • right-first-time urine analysis, diagnosis and treatment - don't see the same patient twice for the same problem
  • delivers specimen into 10ml tube that fits most automated laboratory urine analysers (no decanting in lab)
  • no soiling, dry tube, clean toilets: more hygienic for healthcare professionals
  • targeted prescribing, reducing need for broad spectrum antibiotics
  • improved infection control: no spills or splashing of urine
  • works equally for men, women and children (from toddler age)
  • excellent for pregnant women where antenatal screening must be super-accurate; they don't have to see the funnel is in place - they can feel it
  • antenatal screening accuracy for maternal diabetes, pre-eclampsia
  • excellent for the elderly prone to UTI, which can affect both wellbeing and behaviour
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
  • West Midland Patient Savings of £90 (please see attached WM cost savings model, Patient Savings tab)
  • Accurate urine specimens mean prompt, accurate diagnoses
  • Patients will no longer need to visit their GP more than once for urine-related illnesses
  • They will receive the correct, targeted antibiotic, helping the fight against anitmicrobial resistance, encouraged by over prescribing of broad spectrums
Current and planned activity: 
  • Peezy Midstream is on the NHS Supply Chain at 87p (Peezy, tube, genital wipe)
  • It is approved by NHS Prescription Services and on the Drug Tariff for prescribing
  • Quality Improvement Audit at Barts (London) shows reduction in mixed growth from 17.5% to 1.5%
  • Quantative clinical study results pending from Stanford Medical School
  • Peezy currently part of MS Rapid Diagnostics Pilot, London
  • Prescribing growing amongst antenatal population
  • In use within some NHS departments: urology, outpatients, pre-admission, antenatal, A&E, Ambulance Services
What is the intellectual property status of your innovation?:
Patent and trademark granted:
  • UK
  • USA
  • Europe
  • China
  • Australisa
  • Asia
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Easy; Peezy is available through the NHS Supply Chain
Forte Medical is happy to attend your location and brief staff on usage and instructions if necessary
Measures:
Reduced mixed growth
Reduced retesting
Reduced repeat appointments
Cost and efficiency savings
Adoption target:
6 months
Read more
Hide details
Giovanna Forte 09/11/2016 - 14:50 Detailed Submission 1 comment
4.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Peezy Midstream delivers right first time urine analysis, diagnosis & treatment by reducing mixed growth from national average 18% to 1.5%. Reduces costly retesting, repeat appointments and unnecessary antibiotic prescribing. Saves time and money.
Overview of Innovation:
Peezy Midstream is new technology that guarantees midstream urine for essential tests and routine screening. It reduces the national average mixed growth rate from 18% to 1.5%; Peezy meets all the criteria for the Department of Health's Getting It Right First Time Programme.

Peezy is on the NHS Supply Chain and the National Drug Tariff, which means it can be prescribed for antenatal and elderly use, where truly accurate results are essential for mental and physical wellbeing of patients.

Urine analysis is used for myriad routine and exceptional diagnoses from chronic urinary tract infection to bladder cancer; prompt and efficient treatment brings benefits to clinicians and patients alike saving valuable time and money.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Giovanna Forte 21/11/2016 - 13:10 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Heart DNA is a genetic testing kit for patients at increased risk of developing atrial fibrillation and other cardiovascular diseases, the results are reviewed and assessed by a consultant who is well informed about the patient’s medical history.
Overview of Innovation:
“Heart DNA” is a genetic testing service for patients at increased risk of developing cardiovascular diseases and for cardiologists and genetic counseling officers/geneticists who would want to work with us in delivering this service to the public.

We are partnering with healthcare professionals who will review (online) the genotyping reports coming from our well established partner lab and will be giving their health assessment based on both: the patient’s health profile/medical record, which our users will be asked to fill in early on our website, and on the genetic predispositions that may be found in the patients DNA. In esssence, our consultants will be able to give an informed screening assessment that covers: the detection of inherited conditions and an assessment to the patients’ response to certain drugs that may well be administered to treat CVDs.

Heart DNA is a simple saliva-based test that is supported by scientifically validated research and an extensive amount of studies. Heart DNA analyses the patient’s unique genetic markers, which influence a broad range of heart-related conditions, our gene panel list consistc of 96 markers that cover: Atrial Fibrillation, Coronary Artery Disease, Myocardial Infraction, Cholesterol levels, and risks for hypertension. It can also help identify a patient’s propensity for increased risk towards certain heart medications, eight classes of drugs that affect the cardiovascular system are examined; anti-platelets, anti-coagulants, statins, stimulants, beta-blockers, ACE inhibitors, calcium channel blockers and hormone therapies.

Our test provides information that allows Doctors to;
1. Monitor a patient’s specific health conditions thoroughly.
2. Prescribe a more optimal medication and dosage for a patient.
3. Suggest early lifestyle and diet interventions to help combat and prevent certain heart conditions.

Overall, the aim is to enable doctors and patients to bridge the gap in genetic information that has proved over an extensive amount of studies and research to be pivotal in the design of better prevention and treatments regimens. Our focus is to cause a change in the architecture of complex care routines that would address the challenges of working at scale, and which can capitalize on the associated opportunities that we will enable by striking business partnerships with medical consultants to create and deliver a distinctive competitive advantage over all competing genetic testing companies. 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
DNA testing is not available at the point of care, regardless of its imperative potential to mitigate treatment regimens and enhance disease prevention pathways. Moreover, once an individual is diagnosed as having a cardiovascular condition, the challenge exist in prescribing the right medication at the right dose in the right time.
Tools promoting optimal direction for healthcare service and moving patients towards the digital space will be hugely disruptive in a market where faster processes and cheaper costs are imperative to its evolution. Products that can enhance the working process inside GPs offices and provide more rapid, reliable and robust diagnosis decisions within primary care, that could enhance workflow for healthcare professionals, assisting earlier triage and potentially redesigning GP care pathways; such products have the potential to save the healthcare and biotech industries over £1bn every year, just in labour time. 

The current pathway to obtain a genetic test for a single cardiac condition through the NHS is lengthy, complex, costy and is not accessible for everyone; with multiple visits and referrals to see healthcare specialsits (Annex; Figure 1). 
Our system workflow has been designed to empower patients within an innovative framework, that ensures having a certified partner cardiologist assessing their health condition before a patient can receive his/her genotyping results. It will also ensure that patients and doctors have an easy access for booking appointments to follow up, when the need is present. Our comprehensive service will cut down the turn around time from several months to 2 weeks with as little steps as the figure shows (Annex; Figure 2). 

Moreover, our database will later provide an electronic medical record through which other healthcare consultants can opt to review when they need to access the patient’s genotype before prescribing a certain drug at any stage of the patient’s life. Thus, cutting down the path of trial and error before the the right medication is prescribed to the patient. 

Early screening for genetic predispositions and having an early risk assessment for patients who may develop Arterial Fibrillation or any other CVD will significantly allow the NHS mitigate prevention regimen for the general public before they become patients. Thus, signinficantly reducing the £15bn bill of CVDs every year (BHF stats 2015).

 
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The major risk factor associated with Atrial Fibrillation and all other CVDs is having a family history with the disease. By family history we are referring to the genes that have passed from the parents to their offspring, which (if found to be mutated as well) can increase the risks of that individual developing the same disease. 
While it is well accepted that such risk factor could not be changed or adjusted (at least for the time being), hence the term "non-modifiable" risk factor, it is also accepted that if such risk is detected then the patient would be better positioned to manage the other "modifiable" risk factors early on, which can significantly change the course of the patient's life and the development course of his/her inherited condition. 

We believe that well informed and educated individuals about their risk factors will allow them take better decisions and have more enlightened judgments when it comes to managing their risk factors and altering their lifestyle and daily habits. Modifiable factor like quite smoking, being fit, eating healthy and managing diabetes, obesity and cholesterol levels, are all found to be imperative in managing AF and other CVDs from an early stage, the earlier the intervention, the better the outcome. 

Moreover, we believe the greatest benefit to the WM population will come at a later stage through our Data Bank which will provide the perfect reference tool to better direct prevention and treatment regimens withihn the WM population, risk factors such as race, age and sex will all be considered in the future direction towards an advanced and precise person-centerd system.



 
Current and planned activity: 
Business partnerships have all been established for the development and delivery of our product/service. Funding is currenly sought to finance our outsourcing agreements:
  • Genotyping analysis will be conducted at a well established genotyping lab in the UK.
  • Our saliva collection kits will be outsourced from a supplier in the UK. 
  • Our service content is all in place and the gene panel list has been put together through an extensive amount of well researched and accredited reference genetic testing studies, the online platform will be developed by website developement agency in Birmingham.
  • Our box and packaging have been designed and the order is to be placed.
  • An initial agreement has been established with a reputable cardiologist consultant to review the patients results and put his recommendations to each genotyping report being assessed.
  • A pilot study is currently being designed by our Medical and Research Officers (both are GPs at the QE hospital). 


 
What is the intellectual property status of your innovation?:
The company will be developing additional patents and intellectual property related to response and side effect prediction for further treatments of hypertension and other Cardiovascular disorders through its DTC kits and the databank that it will generate from its lab based genotyping services. These will be offered to the BHF and all other concerned research groups in the field of Cardiac Health.

In terms of our regulatory path, there are no specific regulations outside consumer protection, data storage, and for storing biological samples “saliva” we will apply control regs that deal directly with this. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
Please refer to our commercial information section (Business Strategy)
Measures:
​We are here to help; we believe that we have a relevant and compelling solution that (if adopted) can save lives and enhance the prevention and treatment regimens for patients with cardiovascular conditions.
We will measure our performance based on the value that we are delivering. Hence, by the end of year one we are looking to exceed the 1000 kits sale and have a strong clinical data that would support our proposition, in regards to giving patients better options to mitigate their risk factors and to healthcare professionals to administer drugs that are better suited for certain subpopulations; based on genetic makeup and the health profile "environmental factors" for each individual patient.
These assessments will be made through our end of year statistical study that we will run on all the patients whom we have tested. 
Adoption target:
The adoption target is to demonstrate a successful, valuable and cost efficient systematic framework that would address the core objectives of the NHS Sustainability and Transformation Plans in drving a genuine chnage to patients experience and health outcomes of the longer term.
Read more
Hide details
Abdullah Sabyah 26/11/2016 - 14:10 Sign Posted 12 comments
0
0
Votes

Innovation 'Elevator Pitch':

Heart DNA is a genetic testing kit for patients at increased risk of developing atrial fibrillation and other cardiovascular diseases, the results are reviewed and assessed by a consultant who is well informed about the patient’s medical history.
Overview of Innovation:
“Heart DNA” is a genetic testing service for patients at increased risk of developing cardiovascular diseases and for cardiologists and genetic counseling officers/geneticists who would want to work with us in delivering this service to the public.

We are partnering with healthcare professionals who will review (online) the genotyping reports coming from our well established partner lab and will be giving their health assessment based on both: the patient’s health profile/medical record, which our users will be asked to fill in early on our website, and on the genetic predispositions that may be found in the patients DNA. In esssence, our consultants will be able to give an informed screening assessment that covers: the detection of inherited conditions and an assessment to the patients’ response to certain drugs that may well be administered to treat CVDs.

Heart DNA is a simple saliva-based test that is supported by scientifically validated research and an extensive amount of studies. Heart DNA analyses the patient’s unique genetic markers, which influence a broad range of heart-related conditions, our gene panel list consistc of 96 markers that cover: Atrial Fibrillation, Coronary Artery Disease, Myocardial Infraction, Cholesterol levels, and risks for hypertension. It can also help identify a patient’s propensity for increased risk towards certain heart medications, eight classes of drugs that affect the cardiovascular system are examined; anti-platelets, anti-coagulants, statins, stimulants, beta-blockers, ACE inhibitors, calcium channel blockers and hormone therapies.

Our test provides information that allows Doctors to;
1. Monitor a patient’s specific health conditions thoroughly.
2. Prescribe a more optimal medication and dosage for a patient.
3. Suggest early lifestyle and diet interventions to help combat and prevent certain heart conditions.

Overall, the aim is to enable doctors and patients to bridge the gap in genetic information that has proved over an extensive amount of studies and research to be pivotal in the design of better prevention and treatments regimens. Our focus is to cause a change in the architecture of complex care routines that would address the challenges of working at scale, and which can capitalize on the associated opportunities that we will enable by striking business partnerships with medical consultants to create and deliver a distinctive competitive advantage over all competing genetic testing companies.
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
DNA testing is not available at the point of care, regardless of its imperative potential to mitigate treatment regimens and enhance disease prevention pathways. Moreover, once an individual is diagnosed as having a cardiovascular condition, the challenge exist in prescribing the right medication at the right dose in the right time.
Tools promoting optimal direction for healthcare service and moving patients towards the digital space will be hugely disruptive in a market where faster processes and cheaper costs are imperative to its evolution. Products that can enhance the working process inside GPs offices and provide more rapid, reliable and robust diagnosis decisions within primary care, that could enhance workflow for healthcare professionals, assisting earlier triage and potentially redesigning GP care pathways; such products have the potential to save the healthcare and biotech industries over £1bn every year, just in labour time. 

The current pathway to obtain a genetic test for a single cardiac condition through the NHS is lengthy, complex, costy and is not accessible for everyone; with multiple visits and referrals to see healthcare specialsits (Annex; Figure 1). 

Our system workflow has been designed to empower patients within an innovative framework, that ensures having a certified partner cardiologist assessing their health condition before a patient can receive his/her genotyping results. It will also ensure that patients and doctors have an easy access for booking appointments to follow up, when the need is present. Our comprehensive service will cut down the turn around time from several months to 2 weeks with as little steps as the figure shows (Annex; Figure 2). 

Moreover, our database will later provide an electronic medical record through which other healthcare consultants can opt to review when they need to access the patient’s genotype before prescribing a certain drug at any stage of the patient’s life. Thus, cutting down the path of trial and error before the the right medication is prescribed to the patient. 

Early screening for genetic predispositions and having an early risk assessment for patients who may develop Atrial Fibrillation or any other CVD will significantly allow the NHS enhance its' treatment regimen for the general public and prevent high risk individuals from becoming patients. Thus, causing a substantial reduction in the £15bn bill of CVDs every year (BHF stats 2015).
Online Discussion Rating
6.00 (1 ratings)
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The major risk factor associated with Atrial Fibrillation and all other CVDs is having a family history with the disease. By family history we are referring to the genes that have passed from the parents to their offspring, which (if found to be mutated as well) can increase the risks of that individual developing the same disease. 

While it is well accepted that such risk factor could not be changed or adjusted (at least for the time being), hence the term "non-modifiable" risk factor, it is also accepted that if such risk is detected then the patient would be better positioned to manage the other "modifiable" risk factors early on, which can significantly change the course of the patient's life and the development course of his/her inherited condition. 

We believe that well informed and educated individuals about their risk factors will allow them take better decisions and have more enlightened judgments when it comes to managing their risks and altering their lifestyle and daily habits. Modifiable factor like quite smoking, being fit, eating healthy and managing diabetes, obesity and cholesterol levels, are all found to be imperative in managing AF and other CVDs from an early stage; the earlier the intervention, the better the outcome. 

Moreover, we believe the greatest benefit to the WM population will come at a later stage through our Data Bank which will provide the perfect reference tool to better direct prevention and treatment regimens withihn the WM population, risk factors such as race, age and sex will all be considered in the future direction of our research through our advanced and precise person-centerd system.
 
Current and planned activity: 
Business partnerships have all been established for the development and delivery of our product/service. Funding is currenly sought to finance our outsourcing agreements:
  • Genotyping analysis will be conducted at a well established genotyping lab in the UK.
  • Our saliva collection kits will be outsourced from a supplier in the UK. 
  • Our service content is all in place and the gene panel list has been put together through an extensive amount of well researched and accredited reference genetic testing studies, the online platform will be developed by website developement agency in Birmingham.
  • Our box and packaging have been designed and the order is to be placed.
  • An initial agreement has been established with a reputable cardiologist consultant to review the patients results and put his recommendations to each genotyping report being assessed.
  • A pilot study is currently being desinged by our Medical and Research Officers (both are GPs at the QE hospital).
What is the intellectual property status of your innovation?:
The company will be developing additional patents and intellectual property related to response and side effect prediction for further treatments of hypertension and other Cardiovascular disorders through its DTC kits and the databank that it will generate from its lab based genotyping services. These will be offered to the BHF and all other concerned research groups in the field of Cardiac Health.

In terms of our regulatory path, there are no specific regulations outside consumer protection, data storage, and for storing biological samples “saliva” we will apply control regs that deal directly with this. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
Please refer to our commercial information section (Business Strategy)
Measures:
We are here to help; we believe that we have a relevant and compelling solution that (if adopted) can save lives and enhance the prevention and treatment regimens for patients with cardiovascular conditions.
We will measure our performance based on the value that we are delivering. Hence, by the end of year one we are looking to exceed the 1000 kits sale and have a strong clinical data that would support our proposition, in regards to giving patients better options to mitigate their risk factors and to healthcare professionals to administer drugs that are better suited for certain subpopulations; based on genetic makeup and the health profile "environmental factors" for each individual patient.
These assessments will be made through our end of year statistical study that we will run on all patients whom we have tested. 
Adoption target:
The adoption target is to demonstrate a successful, valuable and cost efficient systematic framework that would address the core objectives of the NHS Sustainability and Transformation Plans in drving a genuine chnage to patients experience and health outcomes of the longer term. 
 
Read more
Hide details
Abdullah Sabyah 30/11/2016 - 09:18 Approved Login or Register to post comments
3.7
3
Votes

Innovation 'Elevator Pitch':
We develop board games that engage and educate frontline staff. 
They improve care delivery and patient safety by giving staff the knowledge, skills and confidence to make beneficial changes.
Overview of Innovation:
Since 2004 we have been developing board games that improve learning and development by making face-to-face engagement easier and more effective. They bring staff together and encourage them to discuss new ways of working. They get people talking and sharing; players learn from each other.
 
Our games improve performance by delivering the knowledge, skills and confidence that staff need to change the way they work, communicate and behave. Games encourage players to relax and have fun making them more receptive to new ideas and more willing to discuss difficult subjects. While the games are delivering structured and engaging learning it doesn't feel like formal learning. This is very important for unqualified support staff (bands 1-4) who may have fear of formal classroom learning for a variety of reasons.

Our games are designed to be extremely flexible and can be played in the workplace without a specialist facilitator or as part of a more structured formal training programme or workshop. This is intentional and is designed to bridge the gap between solitary learning such as eLearning (which may not be engaging or effective) and formal instructor lead training (which can be effective but expensive and scarce).

We have developed over 40 games and most of them are specifically for use in health and social care settings to address specific clinical and organisational issues. Many of the games are designed to reduce avoidable harm and improve patient safety by encouraging continuous improvement among frontline staff. Games cover a range of issues including:
  • Medication errors
  • Sepsis management
  • Pressure ulcer prevention
  • Malnutrition & dehydration
  • Dysphagia management
  • Stroke pathway
  • Communication skills
  • Team working in health and social care
  • Information governance
  • Genomics
  • Cystic Fibrosis (for children with CF)
All of our games are developed in partnership with leading academics, clinical practitioners, educators and frontline staff. We have formal agreements and partnerships with a range of national and local NHS organisations including NHS England, Health Education England, NHS Improvement, NHS Scotland, and NHS Education for Scotland.

We have formal partnerships with a range of organisations in the Midlands including City University Birmingham, Birmingham Community Healthcare NHS FT, Health Education West Midlands, Coventry & Warwickshire Partnership NHS Trust.

Our biggest challenge is publicising our games. This is why we would like funding from the SME Innovation Fund.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Patient safety and avoidable harm are huge problems for the health and social care systems and for wider society. Many of the changes needed to improve safety are relatively simple and can be carried out by frontline staff without the need for new equipment or complex system or process changes. But these changes cannot happen without effective training and support. Without them frontline staff cannot improve their performance. While evidence based medicine is practiced it is not supported by evidence based training and we believe that within health and social care training is either absent or has no evidence to support its efficacy.

The widespread adoption of eLearning and other remote learning resources are appealing to the organisation because they appear cost effective but can be isolating and unpopular with frontline staff. It's easy to conclude that if these methods of delivering training were effective then the incidence of avoidable harm and patient safety incidents would have decreased or disappeared. They have not.

We believe that the most effective way of engaging and training frontline staff is face-to-face in groups where staff members learn from each other. If this happens it often involves a slide show or lecture and neither of these engage the learners in any discussion nor challenges them to process new information and ideas.

We develop board games to achieve these levels of engagement. A simple board game based on recognisable games such as Snakes & Ladders are very simple to play, widely recognised and have cross cultural and generational appeal. Our games don't require any structured facilitation and can be played by anyone anywhere. Within minutes players are laughing and joking while focussing intently on discussing the questions and scenarios presented within the game.

Independent university and NHS studies strongly suggest that our games are very effective for knowledge transfer, knowledge retention and developing the confidence players need to implement what they've learned during the game. There are also clear indications, from within the NHS and care homes, that playing games can have a measurable effect on patient safety and avoidable harm but this needs more investigation to confirm. 

Any reductions in avoidable harm and improvements in patient safety will have a significant benefit on finances across the system and of course the benefit to patients and carers is clear. Staff morale can also be improved.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As described earlier in this submission we have contractual and commercial relationships with several organisations in the West Midlands. The sale of our games generates revenue for these organisations that can be reinvested by them to improve the services that they deliver to the residents of the WM. We anticipate more of these commercial relationships as our company grows so our games would be creating wealth within the WM economy.

The direct benefits to patients and carers of less avoidable harm and improved patient safety is clear and the financial implications for the WM economy could also be significant.

The reputational benefits for service providers should not be ignored and the improvements in staff morale could also be a beneficial side-effect.
Current and planned activity: 
We have formal agreements and partnerships with a range of national and local NHS organisations including NHS England, Health Education England, NHS Improvement, NHS Scotland, and NHS Education for Scotland.

We have formal partnerships with a range of organisations in the West Midlands including City University Birmingham, Birmingham Community Healthcare NHS FT, Health Education West Midlands, Coventry & Warwickshire Partnership NHS Trust.

We also have relationships with a range of Royal Colleges, charities and patient groups including Royal College of Nursing, Royal College of Midwives, The Patients Association, UK Sepsis Trust, Chest, Heart & Stroke Scotland and the British Dietetic Association.

We cannot develop our games without the support of subject matter experts from these organisations and we will continue to strengthen these relations and create new ones.
 
What is the intellectual property status of your innovation?:
In most instances we entirely own the IP related to our games. In some instances the IP is owned, or partly owned, by our partners and we sell the games under licence from them. We recently had an IP Audit carried out on all of our games and associated commercial agreements and partnerships. When this report is finalised we would be willing to share it with the SME Innovation Fund.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
In terms of scalability many thousands of existing games are already being used in hospitals, universities and care homes across the UK and overseas. The WM is well-represented in terms of games already in use. Funding from the SME Innovation Fund would be used to broaden the scope of existing activities and ensure that more games are sold and used in the WM and elsewhere.
Measures:
Because this submission is related to the promotion of a range of products success will be measured in numbers of additional games sold. However, individual games are assessed for their efficacy in knowledge transfer, knowledge retention and confidence levels of players to make changes to care delivery and behaviours. Independent studies carried out by universities and NHS employees all conclude that the games are effective. We assume that more games being used by frontline staff will translate into improved care delivery.
Adoption target:
The company is currently viable. The loan would help generate extra sales and this revenue will be used to further grow the business. Existing games cover almost the entire health and social care sector and so potential buyers and users in the WM could be any NHS trust, university, care home or other service-provider.
Read more
Hide details
Andy Yeoman 09/12/2016 - 16:19 Sign Posted 2 comments
3.2
2
Votes

Innovation 'Elevator Pitch':
Our invention will monitor vitally and medically significant parameters (blood microcirculation) in real time, wirelessly supplying individuals with efficient CV information to smartphones
Overview of Innovation:
In the next few years, non-invasive technology will have revolutionised medicine. Wearable devices and smartphones can serve as the hub for new diagnostic and treatment technologies. With new tech will come new opportunities for our healthcare: improving the accuracy and usefulness of information we can gather on our health as citizens and patients; changing how and where care is delivered; offering new ways to prevent, predict, detect and treat illness. Aston Smart Light Ltd. (ASL Ltd.) focuses on the development of advanced medical tech to continuously monitor human health state and will potentially aid in the development of fast and affordable body control without specialist knowledge. Our mission is to employ this experience and our previously developed devices to release cutting edge technology more complex and clinically informative than anything currently available, to the specialised and commercial markets. Our inventions relate to non-invasive devices that are suitable for simultaneous monitoring of body conditions. The main goal is to perfect the technology as well as manufacture a smartwatch style device capable of monitoring human body conditions, while wirelessly sending this information to your smart phone.
 
SmartWatch is a highly innovative project. The aim of this project is to manufacture a smartwatch style device capable of monitoring human body conditions based on Doppler flowmetry (DF) for healthcare and self-monitoring. Such monitoring is required in hypertensive patients to prevent heart failure (HF) and acute ischemic stroke (AIS) as well as for individuals seeking control of their physical and emotional state. The research, based on ultra-low power laser devices will advance the field of personalised medicine by allowing the watch-like devices design and fabrication. The proposed device will provide constant monitoring of patient cardiovascular conditions and would allow doctors and to give personalised advice and treatments. While there are devices already providing health monitoring, all of them are based on heart rate sensing and cannot monitor advanced health condition. Our smartwatch style device is suitable for detection of blood microcirculation and represent an entirely new, clinically relevant application with no current competition.
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
N/A
Read more
Hide details
Igor Litvinov 02/02/2017 - 14:55 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Aptvision is revolutionary to the radiology sector providing a paperless & cost effective workflow.  Designed with radiology experts, practiced in-depth and customised to meet the specific needs of today’s modern & demanding radiology environment.
Overview of Innovation:
Total Radiology Solution including RIS and other innovative solutions has been designed to increase efficiency in hospitals and clinics - not just to store patients’ data. It’s unique innovation can be seen in:
  • Cost savings and increased productivity
  • Increase revenues for hospitals and clinics: web booking, schedule optimisation
  • Reduce errors and staff duties
 
Aptvision RIS is the most innovative RIS on the market offering fully paperless workflow from start to finish: eReferral letters automatically attached to the RIS, e-consent forms, Online Results, etc. Aptvision RIS also assures:
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • Fully web based, no installation - just the web browser
  • Ability to report on studies from any location without a need of installing dedicated software on individual doctor’s PC.
 
Much more than a standard RIS, Total Radiology Solution offers:
  • Fully integrated Web Booking in which patients can book their appointment like a seat on an airplane. From the clinic’s website patients can see which appointments are available for the type of exam they need and book it immediately.
  • Aptvision’s system automatically provides a call back from a clinic’s Call Centre, to verify the selected appointment and go through safety questions. The operator is prompted by the system to ask the appropriate questions.
  • This feature has reduced the 40% dropped calls rate to zero and practically eradicated no shows and errors.
  • Before the appointment, the patient receives a SMS Reminder of their visit and gains access to the Online Consent Form. They can complete it on their phone or computer before their visit day.
  • On the appointment day, patients can use Online Registration in the clinic using the interactive kiosk or tablet & without the need to stand in a long queue at the reception. They can also monitor their live updated waiting time on dedicated monitors.
  • The electronic consent form as well as all previous medical history is attached to patient’s record in Total Radiology System leading to completely Paperless Workflow. Once the appointment is completed, patient is informed with an SMS telling them their results are ready and can be viewed in the Online Results portal if this is appropriate.
  • Voice Recognition to more quickly create medical reports
  • Scan Audits to improve the quality of the reports and enable sharing of expertise.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Revenues increase
  • Across 16 clinics in Ireland we have facilitated savings of up to €600,000 per clinic through reducing no-shows, errors and through modality optimisation
  • We have also increased revenues by €2.4 million in an 18-month period through web-booking and e-referrals
 
Efficiency increase and cost reduction
Through fully paperless workflow
  • An advanced, configurable, fully integrated e-referral platform feeding actual availability of modalities
  • E-referral letters automatically attached to the RIS, e-consent forms, Online Results, etc
  • Electronic access to all documentation and forms
  • Quick access to all medical history
  • ensure scan is possible and safe for patient (availability & safety questions)
Reduction of manual processes
  • Fully business rules driven without manual intervention
  • Built-in processes for auto scheduling and bulk appointment operations
  • No re-typing of information
  • No web booking missed
  • Medical call centre takes over all calls so reception could focus on patients and their needs
  • Interactive kiosks, tablets and monitors allow patients to register online without a need to come to reception
Improved Patient satisfaction
  • Reduced waiting times for scans and results
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
 
Quality improvement
Peer review feature that allows anonymous review of radiology reports by random peer
 
Better hospital/clinic management
Live updated personalized dashboards for quicker decision making and detailed reporting: revenue reports, comprehensive operations reports, etc.
 
Savings in time
  • Quick system implementation - within few days, not months
  • Easy and intuitive up and running in 30 mins
  • Improvements visible from day one
 
Existing customers have reported statistics of:
  • Modalities capacity increase of 30%
  • 1 extra scan per hour
  • 10 more booking per day
  • Reduced reporting time 20min -> 4min
  • 50 reports per day vs 15
"Aptvision is revolutionary to the radiology sector and is the key to a paperless workflow. It improves daily operations and leads to quicker reporting times and early diagnosis. My experience suggests that Aptvision RIS increases a clinic's efficiency and bottom line from day one and has been the answer to our digital problem in one step."

Prof. Michael Maher
Consultant Radiologist, Cork University Hospital
Professor of Radiology, University College Cork
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
With rapidly increasing demand for diagnostic imaging and hospital and clinics workflow heavily relying on paper and manual duties radiology providers are sometimes unable to cope with that increased demand and provide their diagnostic in efficient and timely manner which can result in patient dissatisfaction and in some cases even lost lives.

Aptvision Total Radiology Solution offers a solution that can revolutionize radiology industry by promoting efficiency and paperless workflow that increases productivity in hospitals and clinic and ultimately benefits patients and their lives.
Our innovative features can benefit patients in numerous manner including:
  • Better and quicker access to radiology
     
  • Reduced waiting times for scans and results which can save lives
     
  • Ensures patients safety and enhances patient experience at all stages of their appointments (web booking, online forms and results, SMS notifications, online registration etc.)
     
  • Quality improvement - Peer review feature that allows anonymous review of radiology reports by random peer. It improves the quality of the reports, enhances share of expertise and allows discussion of interesting cases with experts in anonymous manner. This hugely benefits patients and again helps to save lives
     
  • Make use of modern ecommerce technologies to patients
Current and planned activity: 
Aptvision has just completed the Serendip programme.

We have applied for late inclusion into supplychain RIS/PACS frameworks.

We are actively engaging with Queen's hospital (BHR hospitals trust). We have presented the system and received a very positive response and we are currently organising a full day workshop with all staff.

We are presenting shortly to Black County Alliance.

We are seeking to work in partnership with an NHS Trust to deliver an early demonstrator for the NHS.
What is the intellectual property status of your innovation?:
Full intellectual property of all applications and solutions is owned by Aptvision Ltd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Fiona Smith 14/02/2017 - 11:23 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
A modular university accredited programme which builds the skills, understanding, tools and confidence of NHS junior and middle managers to implement innovations leading to greater efficiency and rapid improvement in services for patients
Overview of Innovation:
The gap between research evidence and practice is significant for healthcare organisations.  Healthcare interventions which we know to be effective can take a long time to enter common practice, whilst others which we know to be ineffective can take a long time to be discarded. The implementation rates of quality improvement (QI) initiatives, for example, are believed to be lower than 50%. Implementing innovations is demanding of employees and organizations--cognitively, emotionally, and physically.. When attempting to implement innovations, organizations face challenges such as misaligned incentives, professional barriers, competing priorities, and inertia.
Studies of innovation implementation in health care settings have shown that middle managers can play an important role in enabling innovation, and supporting healthcare innovation implementation as information brokers - communicating, diffusing and mediating information flow between senior leaders and frontline staff. Middle managers with the capability and confidence to innovate and to lead service improvements are therefore essential if the NHS is to deliver radical and transformational change across whole healthcare systems. But evidence suggests that middle managers are often slow to adopt innovations, whether through generating ideas for improvement or creating opportunities for spread of good practice across departments and organisations.The enablers for junior and middle managers to become improvement leaders have been identified as:
  • proficiency with management skills and tools, (including financial, HR and workforce, programme, operational and strategic management),
  • skilled use of improvement science and quality methods,
improved personal impact on the wider system, through understanding how to influence, motivate and engage effectively with other practitioners at all levels. 

This new programme seeks to bridge the research/practice gap through combining academic theory and conceptual frameworks with practical skills-based learning and behavioural development approaches to support junior and middle managers to become confident improvement practitioners. The programme combines classroom-based learning with application to identified improvement projects, ensuring that academically-rigorous teaching is linked to work-based practice and is grounded in the needs of managers, their organisations and the people who depend on health services. 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Every £1 spent on management development in the NHS needs to  be  justified.  Research   suggests   that   the   financial   benefits of   effective  programmes  are  potentially  hugely  significant:  equivalent  to  up  to  £15,000 per programme participant due to staff retention, innovations and  improvements  which  lead  to  cost-benefits  and  better  patient outcomes.   This   is   set   against   an   average   programme cost per participant of <£5500.
The development of junior and middle managers with the confidence and capability to lead and support innovation and improvement will have multiple benefits for the NHS. For instance, the swifter adoption of improvements in process efficiencies will generate cost benefits; innovations in support to patients will lead to improvements in patient experience; adoption of new technologies will lead to innovative ways of working across multi-professional teams; the spread of good practice will be enabled.
The programme will be relevant to acute, community and mental health organisations across the West Midlands.Relevance to primary care and general practice will also be key, and longer term to social care providers potentially.  It should also be noted that these organisations are small and medium enterprises and by coming together on this programme may generate opportunities for collaborative improvement efforts.
Through the development of a cadre of peer-evaluators the programme will also support the building of a critical mass of junior and middle managers in the West Midlands health system, aiding succession planning and ensuring that the business of innovation and improvement is not confined to senior leaders or to specialist practitioners.
 
 
Online Discussion Rating
5.00 (1 ratings)
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Managers will come to the programme with ideas for a change they want to implement, or recognition of a problem to resolve. These could include a focus on the adoption of new technologies, introducing new skill-mix to service delivery teams, developing fast-track surgical pathways, developing whole system approaches to improving long-term conditions pathways of careasset-based approaches to person-centred care, improvement in the management of mental health problems in A&E, home-based exercise for older people to prevent falls, opportunities for cost-saving through better sharing of data. Since most, if not all, of these issues will call for multi-professional involvement, we will encourage participants to come on to the programme in pairs, trios and small teams. This will aid the rapid spread of ideas for improvement, and have immediate impact on services.
 
The programme will also enable junior and middle managers to swiftly assess and select between competing opportunities for improvement, develop workable project plans and compelling business cases, secure engagement of key supporters and manage resistance, and develop appropriate metrics to measure progress towards anticipated benefits.
The programme will be constructed as a proving ground: a space in which participants can test their ideas for improvement, learn from experience of application and develop the learning, skills and competencies they need to be influential managers. As such the participants will develop their skills as innovators and entrepreneurs.

The programme will use peer-evaluation of progress as an element in the assessment of the Certificate, recognising that one test of managerial skill is the impact on others. In this way participants will become skilled evaluators and assessors of innovation, developing skills which are immediately transferable to the workplace. Finally the design of the programme will enable participants to build relationships across professional and organisational boundaries, one of the key enablers for more effective and productive system-level  innovation
Current and planned activity: 
In 2017 the HSMC undertook research work on behalf of the University of Birmingham Health Leadership Group. This involved meetings and interviews with the most senior leaders in health and social care across the West Midlands to ascertain the learning and development gaps in their workforce. A key theme emerging from this research work was the need in the NHS for further development of the practical skills needed by junior and middle management in order to properly and effectively improve services; implement innovative practices; lead people; manage resources; and enable change. Aligned to this feedback was a request to support team development and multi-professional education and training. We have continued to work with NHS organisations and leaders to develop the ideas which underpin this programme proposal, which now includes opportunities for peer challenge and support, shadowing and developing system sightedness amongst junior to middle managers.
What is the intellectual property status of your innovation?:
The IP resides with HSMC at the University of Birmingham.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
2
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Rejection Reason:
Board decided not to support - feedback provided and innovator decided not to pursue
Read more
Hide details
Anonymous 04/04/2017 - 13:23 Rejected 1 comment
3.5
5
Votes

Innovation 'Elevator Pitch':
Coronary Artery Disease (CAD) is the leading cause of death world-wide. HeartFlow’s non-invasive technology, FFRct, has been found to accurately diagnose patients with suspected CAD, avoid unnecessary invasive procedures, and reduce healthcare costs
Overview of Innovation:
The diagnosis and care of patients with suspected coronary artery disease is significantly improved by the use of HeartFlow's FFRct analysis. Our process starts with data from a standard Coronary Computed Tomography Angiography (CCTA). High-quality (64 slice or greater) CT scanner images are sent to HeartFlow.

HeartFlow then creates a personalized, 3D model of each patient’s arteries. Where computational fluid dynamics are used to evaluate blood flow and assess the impact of blockages in the arteries. With this actionable information, clinicians can determine the right course of action for each patient.

While FFRct is still in an early  stage of adoption, there are now over 150 publications on the technology. Clinical trials have validated both the diagnostic accuracy and clinical utility. Most recently NICE issued guidance on HeartFlow FFRct, stating "The technology is non-invasive and safe, and has a high level for diagnostic accuracy... may avoid the need for invasive coronary angiography... Based on current evidence using HeartFlow can lead to cost savings of £214 per patient."

CT data is securely (Anonymised CCTA data) and seamlessly sent via our “HeartFlow Connect” once installation is approved by the hospital trust. HeartFlow ensures that the scans and FFRct results and analysis models are acceptable to a sites radiologists / radiographers.
 
Whilst this is an emerging diagnostic its well positioned to become an integral part of standard patient care for those who are at risk of CAD. As this is a new technique HeartFlow provides training to radiologists, radiographers, cardiologists and support staff. We work closely with each site to provide support and training to help evaluate the technology and as they begin to incorporate FFRct into their clinical practice. [A high level overview of HeartFlow’s training support can be found in the Adoption guide published by NICE. (see attached)]
 
HeartFlow FFRct users are invited to educational seminars and we are working on establishing a UK users group to help sharing best practice around FFRct’s use.
 
HeartFlow has received CE mark approval for use in UK/Europe.  CCTA image specifications for HeartFlow FFRct analysis; HeartFlow’s CCTA quality requirements are consistent with those of the Royal College of Radiology (RCR), British Society of Cardiovascular Imaging and the Society of Cardiovascular Computed Tomography (SCCT) performance of CCTA guidance document.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The use of HeartFlow FFRct can improve patient care, efficiency, and lower medical costs:

Patient Care
  • HeartFlow FFRct provides a physician with both functional and anatomical data, improving diagnostic accuracy, thus reducing invasive procedures and associated complications
  • Improved diagnostic accuracy improves patient care and quality of life
  • Studies suggest that incorporating FFRct lowers patient radiation levels due to decreased angiography
Efficiency
  • Studies indicate that the application of FFRct may result in a reduction of unnecessary angiographies, improved cath lab efficiency, and reduced waiting lists
  • By providing both functional and anatomic data, physicians may be able to reduce the need for and waiting times associated with other diagnostic imaging tests
Cost of Care
  • As demonstrated in the NICE guidance, the use of HeartFlow FFRct can potentially reduce the cost of care. NICE estimates an average savings of £214 per patient. This saving is based on not conducting inappropriate invasive diagnostics.
  • A Japanese study has indicated that the use of the CCTA-FFRct strategy to select patients for Percutaneous Coronary Intervention (PCI) would result in 32 % lower costs and 19 % fewer cardiac events in 1 year compared to the most commonly used CAG-visual strategies. 
 
“The HeartFlow FFRct Analysis provides a definitive understanding of both anatomical and functional findings, without any additional testing or risk for patients. Application of the HeartFlow FFRct Analysis is likely to transform the quality of care we can provide for patients, ensuring the most accurate diagnosis and the best treatment plan, as well reducing the need for invasive coronary angiography – a procedure not without its risks.”
  -  Dr. Joseph Mills, Liverpoool Heart and Chest Hospital
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
As stated in the NICE guidance, the adoption of HeartFlow FFRct in the West Midlands region could improve patient care and outcomes while generating significant savings for the region.
 
We are looking for additional adoption sites and would be interested in hearing from West Midlands Trusts that would like to take the lead in establishing our UK user group.  
Current and planned activity: 
HeartFlow is in early conversations with NHS Trusts and commissioners. A handful of early adopting NHS medical centres have begun to provide HeartFlow FFRct for their patients. HeartFlow is engaging with interested physicians at centres with high quality CT capabilities.

UK Sites where Heartflow FFRct is being used:
  • St. Bartholomew’s Hospital (London)
  • Liverpool Heart and Chest
  • Russell Hall Hospital (Dudley, West Midlands)
  • Freeman Hospital (Newcastle)
HeartFlow is in discussion with other UK site about adoption of FFRct.

Planned / required activity
  • We are looking for additional adoption sites and would be interested in hearing from Trusts that would like to take the lead in establishing our UK user group 
  • Whilst we have undertaken worldwide studies we are always interested in ongoing evaluation / validation and collaborative developments technically and with clinical pathway integration.
  • In the future we plan on conducting clinical trials based & focused on specifically the UK population.
What is the intellectual property status of your innovation?:
HeartFlow has established significant intellectual property and has been issued several patents.
HeartFlow received CE IIA mark approval for use in UK/Europe in July 2011. The technology is also ISO 13485 certified.  

Return on Investment
Savings have been demonstrated in clinical trials (PLATFORM), third party health economic modelling (NICE guidance, Int’l Journal of Cariology 183 (2015) 173-7), and real world experience at early adopting centres.
 
NICE recommendations for Heartflow FFRct (February 2017) state:  “Using HeartFlow FFRct may lead to cost savings of £214 per patient. By adopting this technology the NHS in England may save a minimum of £9.1 million (annually) by 2022 by avoiding invasive investigation and treatment.  
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Regional Scalability:
Liverpool Heart and Chest has performed more HeartFlow analyses than any other site. They have demonstrated clinical and economic benefits to incorporating HeartFlow FFRct into their practice. The uptake is due in part to to the strong support from their regional CCG.
Measures:
HeartFlow is seeking to achieve the following outcomes:
 - Improved patient care: Reduction in unnecessary invasive angiographies and eventually a reduction in waiting times for those patients that need angiographies
 - Reduction in Healthcare Costs: NICE estimates cost savings of 214 GBP per patient. We are working with existing sites to demonstrate real world outcomes.
 - Quality of Life: HeartFlow's clinical utility trial, PLATFORM, demonstrated an improvement in quality of life when FFRct was incorporated into patient care pathways. It is likely that this is in part due to the avoidance of unnecessary interventions. To date we have not seen any adverse events from avoiding invasive procedures.   
Adoption target:
NICE estimates cost savings of 9.1M GBP annually within five years. To reach this objective approximately 35,000 patients would need to have access to a HeartFlow FFRct analysis. 
Read more
Hide details
Ben Forrest 12/05/2017 - 17:12 Detailed Submission 3 comments
5.7
3
Votes
-99999
Innovation 'Elevator Pitch':
Achiever Medical LIMS helps research institutions to improve lab efficiency, facilitates return on investment into sample collections & demonstrates compliance to legislation. Inbuilt security protects patient identifiable data with controlled access
Overview of Innovation:
With increasingly stringent regulations and greater emphasis on profitability placed on laboratories, Achiever Medical LIMS was designed in conjunction with leading scientists & clinicians to provide an easy-to-use sample management system incorporating sample tracking, clinical data management, workload & communication management. The system addresses the gap left by traditional LIMS systems by providing enhanced donor and research profile data.
 
Achiever Medical LIMS is a process driven & web browser-based laboratory & clinical data management system that is flexible/scalable to evolve as needs develop. Using Open Standards to streamline the sharing of information across existing applications Achiever Medical LIMS allows data to be imported from, e.g. Patient Information & Storage Environment Management Systems, Lab equipment, Emails & Calendars for an holistic overview of samples, equipment, environment & workload.
 
Achiever Medical LIMS enables the mapping of Standard Operating Procedures (SOP) to ensure staff adhere to agreed standards, ensuring regulatory compliance & promoting quality, efficiency & consistency. Achiever Medical LIMS can assist in compliance with the Human Tissue Act, Good Laboratory Practice & CFR 21 Part 11.
 
Sample tracking functionality delivers complete traceability with automatic generation of unique reference numbers for each sample. Core sample details e.g. location/sample type are tracked as values change for a complete audit history. Sample profile information is captured including sample & tissue type, tissue collection details and associated patient & project information. Barcode labels can be generated for single/multiple samples & customised information can be contained within each label. These labels can be scanned to facilitate rapid sample retrieval.
 
Achiever Medical LIMS integrates data and processes across multiple faculties/diverse into a single solution. This enables authorised users to gain an holistic oversight, having full access to complete donor/patient records. Robust security filters and flexible tools within the LIMS allow the creation of custom levels of user security access to samples, donors or project information. This flexibility is especially useful for biobank or bio-repository management or when conducting multiple studies/clinical trials/projects with multiple collaborators. These tools support collaborative working and simplify a task that can otherwise be legislatively difficult and time-consuming.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health
Benefit to NHS:
Achiever’s LIMS ability to quickly and efficiently organise samples for tracking, storage and retrieval, enables the full economic and scientific value of existing samples to be effectively realised and more efficient processing of sample requests and tests.
 
Achiever Medical LIMS enables sample aliquots to be easily generated from the parent record for complete traceability with a sample ‘family history’ view available, from both the parent & child records, allowing rapid navigation between samples within the same family.
 
Tools to enable the detailed tracking & monitoring of a sample via comprehensive sample location & check in/out auditing are provided. These include recording each time the sample is removed from its location, who checked it out and for what purpose. Samples that have been ‘checked out’ are easily identifiable and can be quickly ‘checked in’ when required along with their full audit trail information.
 
Samples used and associated stock depletion during testing or analyses are automatically flagged with Achiever Medical LIMS.
 
Composite samples such as Tissue Microarrays can be easily created within Achiever Medical LIMS, with each individual sample’s position within the composite sample recorded, any requests for removal can be easily and effectively managed.
 
External sample requests received by biobanks & bio-repositories can be managed through Achiever Medical LIMS using its built in management protocols. This facility provides staff with complete chain of custody details for each sample ((the person who requested the sample, reason for request, who approved the request & expected return date (if required) are captured)). Rejected requests are appropriately managed with reasons for rejection being recorded. Where only part of the sample is required, aliquots can be generated for the required amount along with accompanying complete family history record. Dashboards highlight samples due for return, allowing staff to monitor/chase up samples where required.
 
Achiever’s complete sample auditing & sample tracking functionality records changes by staff to core sample information. Audit trail information includes details of specific information fields changed, values pre & post change, date, time and name of the user who made the change etc. Chain of Custody details, including who checked in the sample, to whom it is checked out (where relevant), storage location, details of processing and projects included in are also captured.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
The West Midlands population has access to the most extensive range of specialist tests from a range of stakeholders, showcasing the potential of laboratory contributions to raise the profile of the research, clinical and diagnostic expertise of the region’s NHS laboratory staff.
 
For laboratories, biobanks and bio-repositories sample tracking & donor management capabilities are of huge importance in donor profiling, consent management, traceability, chain of custody & regulatory compliance.
 
The integration of a potentially region-wide system to manage tissue tracking across multiple teams, hospitals and sites can avoid duplication of data entry and maximise data quality while working within the IT and legislative constraints imposed by disparate working environments of the users.
 
Having sought approval for sample collection, samples need to be treated in line with SOPs and available for use in research both internally and with permitted collaborators.  Utilisation of samples is important to maximise the potential benefit from the donor and to make best use of the resources available to clinicians and researchers.  Cost recovery models allow for income generation to promote the sustainability of the biobank.
 
Improving the value of data quality enables laboratory staff and researchers to search for tissue samples from specific cohorts of donors, filtering by level of consent given by donors, allowing them to search for tissues that have not opted out of specific elements of research. This level of capability will allow biobanks and bio-repositories to service very specialist research requests, increasing value.
 
The quality of the donor, consent, storage and tissue viability data greatly increases the value of the tissues to laboratory staff and researchers. Once cleansed, Achiever Medical LIMS’s storage management capabilities help to increase levels of utilisation, reducing overhead costs per sample.
 
The ‘Achiever Medical Researcher Portal’ allows authorised collaborators to view restricted data for relevant samples.  This external view portal promotes the management of sample requests all within a single system, giving an easy means of sharing samples and the relevant data.  Automatic alerts ensure applications are managed efficiently.
 
In addition, reports and analysis providing real-time data, can be run at the touch of a button instead of valuable laboratory personnel spending days (sometimes weeks) painstakingly collating information from various spreadsheets.
Current and planned activity: 
We are a West Midlands based company wishing to work with our regional health providers.  
 
Our current users include Leeds (LTHT), Nottingham (NUH) and Cambridge (CUH) Trusts all of whom use the system to manage their research samples, donor data and to support HTA Audits.
 
Both NUH and CUH use Achiever Medical as part of their involvement with GEL.
 
Achiever Medical is being used to pioneer the data standards being promoted by UKCRC.
 
We would like to work with WMAHSN who are leading the collaboration of The West Midlands Genomic Medicine Centre (WMGMC), a partnership of 18 NHS Acute Trusts across the region, working collaboratively to help to deliver the UK 100,000 Genomes Project.   
We would welcome the opportunity to discuss any requirements for sample management and donor management, projects and disease specific systems for either single organisations or multi-institutional requirements.
What is the intellectual property status of your innovation?:
All IP is owned by Interactive Software Limited.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Read more
Hide details
Sandie Shokar 01/08/2017 - 08:19 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Currently, a GP refers Obstructive Sleep Apnoea patients to an NHS Specialised Sleep Centre. Averaging 24 wks & 3-5 hospital visits before the Patient starts treatment.
Now, a GP with SOMNOtouch can receive results in 48-72Hours (3days vs. 6Mths)
Overview of Innovation:
Currently
The vast majority of patients with Obstructive Sleep Apnoea (OSA) are referred by their GP to a Specialised Sleep Centre at an NHS Hospital with a Average waiting time 12 Weeks


Patients are initially seen by a Consultant or a Sleep Physiologist who would prescribe a Diagnostic Study to be performed either in hospital or at the patient’s home. Average waiting time 12 Weeks
The patient returns to have the sleep study done or to collect the monitor and then returns the device the next day. After a further waiting time of upto 6 Weeks the patient visits the hospital again to obtain the results of the sleep study and if Positive, to discuss treatment.
A letter is sent to the GP informing them of the results and if agreed, a prescription is issued by the GP for the recommended therapy this may also take an average of 6 Weeks to arrive.
 This is prior to any treatment being administered such as a CPAP where if used they attend annually to check on compliance and progress.
 
This 6 month process is dramatically reduced by the S-Med Service to just a few days before an intervention can be delivered.


Now
The GP fits SOMNOtouch, a Combined OSA/Hypertension Monitoring Device to the patient, after 24 hours they return to the GP practice where the device is removed and the GP uploads the data from the device to a secure NHS Digital Cloud Server.
SOMNOtouch NIBP - Five devices in One
Video link: http://www.s-med.co.uk/Products#nav-product-86
 
S-Med Ltd’s Qualified and Registered Physiologists interprets the study and provides a recommendation for further treatment or investigation within 24 to 48 hours to the GP surgery. (All analysis and interpretations are supervised by a senior Consultant).
 
The report is sent to the GP who would then provide a prescription for the relevant therapy to be provided.
 
Thus within 48 to 72 hours a patient can be treated or directed for additional investigations or treatment before their condition deteriorates.

 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Faster response times and time to providing treatment from an average time from referral to treatment of 6 months (24 weeks) down to 4 to 5 days (1 week). With the added benefit if there are more critical underlying conditions then these may be picked up and dealt with quickly
 
Reduction in costs of patients being referred to NHS sleep centres thus less calls and pressure on such specialist clinics e.g.:
 
Reimbursement Tariffs for OSA and Hypertension
Current reimbursement guidelines from the Department of Health are:
  • For Ambulatory Sleep Diagnostic Study: £391.00
  • For 24-Hour NIBP Study: £268.00 (UCL NHS Foundation Trust, there is no NHS tariff)
  • For 24-Hour ECG Study: Recording - £268.00 plus Analysis £215.00 (UCL NHS Foundation Trust, there is no NHS tariff)
 
Cost Savings Calculation
Assuming the following:
  1. Adult Population of the England is Approx. 45 million
  2. BLF figure show approx. 10% of population suffers from OSA = 4.5 million
  3. DH figures show that approx. 30% of adult population has Hypertension = 13.5 million
  4. Public Health England shows that 1.3 million people have Atrial Fibrillation
 
The cost of referring 1% of the above population to hospital annually, will cost approximately:
  1. OSA – 45,000 £32 million per year.
  2. Hypertension – 135,000 £79 million per year
  3. AF – 13,000 £10.5 million per year
 
Total cost of £121.5 million
Cost of S-Med Service - £38.6 million
Savings to NHS = £83 million per year.
 
Aside from OSA, this equipment can be used for chronic heart conditions studies as well as more longitudinal studies adding a wealth of data for clinicians to inform them of patient’s conditions at work, rest and play without the equipment being intrusive and disturbing as current cuff based systems thereby removing the abnormal results they can provide. Thus, this equipment may also be of benefit to clinical trial units or during treatment to monitor the physiological effects experienced by patients undergoing a drug or other clinical interventions. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
In addition to patients getting a faster diagnosis, it will reduce the burdens on NHS Trusts not only from the reduction on 1st line referrals to hospitals, but from patients conditions deteriorating, or suffering economic or social problems waiting 6 months for a diagnosis and treatment to be considered.

North West Innovation Agency (AHSN) will be conducting a pilot which will monitor 75 patients via a number of GP’s Practices. Results should be available by the End of February 2018.
As a West Midlands based company we would welcome an opportunity to work with NHS Trusts and CCG’s within the region to help us grow this service within the UK for the NHS and to increase our team to service and facilitate such requirements.  
Current and planned activity: 
Current NHS engagement
  • Embarking on a NIA application with North West Innovation Agency
  • Submitted an application into the ITP based on experience and adoption within the NWIA area.
  • Considering a NIHR project following a meeting at AHSN meeting - Speaking with West Midlands NIHR/CRN
Requested NHS engagement
  • Procurement / Adoption of: -  Would welcome assistance to gain greater Adoption by Trusts and CCGs within the West Midlands
     
  • Evaluation / Validation / Clinical Trial – Interested in trials for use of our ambulatory equipment (SOMNOtouch) within new clinical areas to show its versatility and extend its clinical use to provide validated evidence within in these new areas.
     
  • Project Assistance S-Med is interested in locating potential clinical / academic collaborators to engage in their current work and to explore other clinical applications of their technology.
What is the intellectual property status of your innovation?:
Device IP held by SOMNOmedics Germany. Clinical diagnostic and reporting service is owned by S-Med Ltd.
Reg. CE0494
We have obtained IGSoC Level 2 (ODS Code: 8JP12)
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Read more
Hide details
Selwyn Sher 03/10/2017 - 12:27 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Woundex is a innovative breakthrough discovery, the only product in the world which efficiently works on all types skin ulcerations, and is one of the best treatments available.
Overview of Innovation:
Diabetic foot problems, such as ulcerations, infections, and gangrene, are the most common cause of hospitalization among diabetic patients. Routine ulcer care, treatment of infections, amputations, and hospitalizations cost billions of pounds every year and place a tremendous burden on the health care system.
 
This therapy will help save the psychological distress people go through when they have amputations. This treatment will reduce the monetary burden on the national health care system. It has shown good results, even on the severe cases of ulcerations.

It has no side reactions. This product can be used in all types of skin ulcerations , open wounds, burns, gangrene  and diabetic ulcers. Patients would be saved from having an amputation.
This product on application helps increase blood circulation around the wound area .It also increases and promotes tissue growth this in turn helps to heal the wound speedily.

 if it is cut, however, in some people with diabetes the skin on the feet does not heal so well and is prone to developing ulcer. This can be even after a mild injury such as stepping on a small stone in your bare feet.
There is reduced sensation of the skin on your feet. Your nerves may not work as well as normal because even a slightly high blood sugar level can, overtime damage some of your nerves. This is a complication of diabetes called peripheral neuropathy of diabetes.
Diabetic ulcers can lead to gangrene , amputation making the patient immobile.
This causes great psychological distress for the patient.
 
Diabetic foot ulcer places a big budgetary burden on the healthcare authorities. Along with treatment of foot ulcers, amputation  the cost are substantial.
The healthcare authorities have to employ multidisciplinary foot care services led by healthcare professionals, and this consist of specialists with skills in the following areas: Diabetology, Podiatry, Diabetes specialist nursing, Orthopaedic surgery, Biomechanics and orthoses, Interventional radiology, Casting and Wound care-putting an even greater financial strain on the heathcare provider.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
Diabetes ulcer and amputations cost £1 in every £150 spent in the NHS budget. Around 15 % of all diabetes patients will suffer from diabetic ulcer and at a advanced stage amputations have to be carried out.  There are currently 150 amputations performed every week in the UK.  Patients who  have diabetic ulcers are given antibiotics as treatment to control the ulcer. These are given over many years. As you may be aware of there is a big problem of antibiotic resistance.
There will be big benefit to the NHS if they use this treatment.
Benefit to WM population:
This Treatment will benefit the WM population in big way and will eleviate the suffering diabetic ulcer patients go through.
Current and planned activity: 
The medicine is a phyto chemical spirit based solution and has to be imported from India. This medicines ingredients can only be grown in India. At the present time this product is being licenced in India
What is the intellectual property status of your innovation?:
At this stage no status
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Ketan Sangani 30/10/2017 - 14:03 Archived 1 comment
Innovation 'Elevator Pitch':
Targeting inflammation to ensure effective resolution of disease. 
Overview of Innovation:
It is extremely rare that a completely new human disease response regulatory pathway is discovered, peer reviewed and published in a periodical of the stature of 'Nature Medicine'. Professor Ed Rainger's team at the University of Birmingham (UOB) have generated compelling evidence to support the existence of just such a pathway. In this new pathway a small peptide (PEPITEM) controls inflammation. The therapeutic restoration of the PEPITEM pathway (by peptide dosing) in diverse pre-clinical models of disease, demonstrates strong curative potential across a broad spectrum of affected organs and tissues. In turn, this provides broad market applicability of PEPITEM based pharmaceuticals. The team have 5 years' of research experience in this respect and the intellectual property for the therapeutic use of the pathway is currently protected by 3 patents held by University of Birmingham. Thus the commercialisation of this technology represents an almost unique opportunity.
 
Viatem Ltd is an asset-centric biopharmaceutical spinout company with a vision to develop a novel class of immuno-modulators that inhibit exaggerated inflammatory responses and accelerate resolution of inflammation. The core competence is know-how and IPR on therapeutic molecules, diagnostic assays, and medical use of PEPITEM and analogues thereof, either as monotherapy, or in combination with clinical standard of care. Investor feedback from a sampling of major VC Funds shows a strong appetite for Series A investment once seed funding delivers a lead compound for development. 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine
Benefit to NHS:
Inflammatory and autoimmune conditions represent an area of significant morbidity and economic burden. Rheumatoid Arthritis (RA) affects 0.8% of the adult population worldwide, with an estimated prevalence in the UK of 690,000 people. RA has a substantial impact on health-related quality of life (HRQoL). Direct NHS expenditure on RA amounts to c. £700 million pa, plus significant spending on social care, both public and private. However, this expenditure is dwarfed by the overall cost to the UK economy of productivity losses due to RA, which was reported in 2010 to be c. £8 billion pa. In the US, societal costs of RA in 2005 were estimated at $19.3 billion increasing to $39.2 billion, including an estimated $10.3 billion for deterioration of Quality of Life and $9.6 billion for premature mortality. According to US CDC estimates, the total costs to the US economy from arthritis and related rheumatic conditions were c. $128 billion in 2005.

Similarly, Inflammatory Bowel Disiease (IBD) represents a very large economic burden, in terms of direct healthcare costs, HRQoL costs and loss of earnings. A US study estimated direct and indirect costs associated with Crohn's Disease and ulcerative colitis, the two most common inflammatory bowel diseases, ranging between $14.6 and $31.6 billion in 2014. In the UK, about 250,000 people suffer from Crohn's Disease and ulcerative colitis, and the total cost of IBD to the NHS has been estimated at £720 million. In Europe, the health economic burden and permanent work disability associated with IBD has been estimated at 4.6 -5.6 billion Euros pa. 
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
The emergence of Viatem as a significant biopharmaceutical company will benefit the West Midlands regional economy and be both a new employer and an important exemplar company in the developing life science cluster in Edgbaston, Birmingham.
Current and planned activity: 
1. Peptide optimisation with screening for solubility, plasma stability, and Physico-chemical stability.
2. Screening of compounds for efficacy and dose ranging.
3. Screening of lead compounds.
4. Protection of new IPR for novel compound(s)
What is the intellectual property status of your innovation?:
The team have 5 years' of research experience in this respect and the intellectual property for the therapeutic use of
the pathway is currently protected by 3 patents held by University of Birmingham
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
4
Regional Scalability:
As Viatem further develops the technology and new drug candidate lead compounds it is intended that therapies may be developed that result in the treatment of diseases, which include rheumatoid arthritis, Type-1-diabetes, Atherosclerosis, Crohn’s disease, Sjogrens syndrome (no therapeutic options available), and Uveitis. The University of Birmingham and the Edgbaston Life Science  Technology Cluster  will benefit from considerable positive publicity.
This will contribute significantly to the development of the entrepreneurial culture within both the MDS College and the wider University, which should assist in retaining and attracting high quality academics and students.

The company will initially be located in the BioHub at the University of Birmingham and will endeavour to remain in the Edgbaston Life Science Cluster.
Measures:
Confidnetial
Adoption target:
Confidential
Read more
Hide details
Anonymous 22/01/2018 - 16:25 Approved 1 comment
3.3
1
Votes

Innovation 'Elevator Pitch':
Watson for Genomics provides peer-reviewed, molecular evidence to help oncologists create personalized treatment strategies for patients based on results from genetic testing of tumour tissue.
Overview of Innovation:
Watson for Genomics analyses and categorizes genetic alterations that are related to cancer progression and provides a list of potential therapeutic options that target each alteration. The interpretation is done within minutes, and a comprehensive report is generated. The summary page of the report lists all the critical genetic alterations that were identified in the analysis and associates each with therapeutic options. Levels of evidence, extracted from relevant literature are provided to show the strength of the evidence.
Watson for Genomics presents findings with evidence via hyperlinks to sources for easy drill down. The drug report section provides details of identified drugs with overview, rationale for the association and level of evidence, as well as recruiting clinical trials.
The molecular profile interpretation provides in depth detail of the known genetic alterations found in the tumour sample. For each mutation, molecular and scientific evidence explaining the pathologic relevance of the alteration is provided. The diagram offers easy viewing of mutations with chromosomal location.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine
Benefit to NHS:
As sequencing becomes more cost-effective, larger gene panels/whole exomes and whole genomes will gain more traction. However, analysis of these will be a challenge, especially using manual methods of curation. Providing rapid cognitive insights to a molecular pathologist will allow genomic testing to become more pervasive and scalable.
Initial Review Rating
3.60 (2 ratings)
Benefit to WM population:
In conjunction with the West Midlands Centre for Genomic medicine, Watson for Genomics will allow genomic testing and personalised treatment options to become more pervasive and scalable in the West Midlands.
Current and planned activity: 
Watson for Genomics is deployed in US. We are currently discussing with several UK Trusts how to bring and prove it in the UK.
What is the intellectual property status of your innovation?:
IP of core product is IBM's
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
David Clarkson 26/02/2018 - 12:26 Publish Login or Register to post comments
3
1
Votes
-99999
Innovation 'Elevator Pitch':
Reduce the time it takes for clinicians to find clinical trial options for patients and increase trial enrollment rates.
Overview of Innovation:
It requires significant time to evaluate open clinical trials, analyse inclusion/exclusion criteria and determine a patient’s eligibility for trials based on all the relevant information in the medical record.
Watson for Clinical Trial Matching eliminates the need to manually compare enrollment criteria with patient medical data, making it possible to efficiently identify the potential trial options. It generates a ranked list of relevant trials for each patient

This increases patient access to clinical research, improves trial enrollment, and reduces trial delays.
See details and a video at: https://www.ibm.com/watson/health/oncology-and-genomics/clinical-trial-matching/
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Innovation and adoption
Benefit to NHS:
Saves time in evaluating Clinical Trials available to your patients and their eligibility. Improves Trial enrollment rates - making new treatments available quicker for patients.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Potential to be the first region in England to use this technology and make trials and new treatments available quicker for patients.
Current and planned activity: 
Currently deployed in healthcare outside UK. We are looking for organisations who will prove the solution works and delivers benefits in the UK.
What is the intellectual property status of your innovation?:
IP is IBMs
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
David Clarkson 26/02/2018 - 13:46 Publish 1 comment
3
1
Votes
-99999
Innovation 'Elevator Pitch':
Peezy Midstream: proven urine collection device, reducing specimen contamination from national average 22.5% to 2.5%. Collects specimen into either 30ml Universal Container or the 10ml lab-friendly Primary Tube. Cost: 87p on the NHS Catalogue.
Overview of Innovation:
Peezy Midstream is a proven urine collection device which reduces contamination risk from a national average 22.5% to 1.5-2.5%. 

The Peezy is key for the pre-analytical diagnostic phase because:
  • The clean collection of Urine is a key component of laboratory medicine, drug and substance testing.
  • Pre-analytical specimen integrity is just as critical to the result reported by the laboratory. Drug testing and clinical laboratories must ensure processes are in place to ensure specimen collection is clean and free of contamination.
  • Contaminates and mixed growth can lead to corrupted or rejected samples.
The Peezy is the only device that provides a clean-catch mid-stream urine, it voids the initial stream into the toilet, removing the need to start-stop-start, it significantly reduces asymptomatic bacteriuria, it is hygienic and has been designed for use in drug testing.

- ISO 15189 / Laboratory Standards
  • Using the Peezy improves ISO 15189 reporting and quality measurements

Adopting the Peezy as the standard model for all urine collection allows laboratories to measure the number of urine samples received in the laboratory uncontaminated and to compare this to the number of contaminated urine samples received as a % of all urine samples processed, a key quality measure of the pre-analytical phase.

Peezy Midstream addresses an overlooked area of diagnostic medicine, delivers accuracy, hygiene and dignity. For those who are elderly or otherwise unable to position the device themselves, help can be hygiencially given with the carer holding the tube in place by the tube. This can be done over the toilet, a commode or bedpan.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Peezy Midstream delivers right-first-time analysis, diagnosis and treatment.

It reduces retesting leading to fewer second and third urinanalysis episodes; use 10 x Peezy kits for the cost of one retest. It promotes right-first-time analysis, diagnosis and treatment and reduced antibiotic prescribing, because the root cause of infection is correctly identified first-time.

Peezy Midstream is hygienic to use, eliminates spills and splashing, results in dry collection tube and dry patient (hands and legs); simply, it promotes infection control.

Peezy meets PHE Microbiology Standars for the Investigation of Urine and WHO standards around the collection of specimens. It meets all available NHS Trust guidelines for midstream urine collection as the recommended standard for urineanalysis. 

Peezy Midstream is easy to use: see our IFU Animation: https://www.youtube.com/watch?v=UTTdiHrtpqY
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Reduced retesting leads to:
  • First time analysis diagnosis and treatment benefits clinician and patient
  • Fewer repeat appointments allowing clinicians to focus on first-time conditions or presentations
  • Reduced  retesting, leads to faster first-time lab analysis on new specimens
  • Convenience to the patient with prompt treatment and reduced repeat appointments
Current and planned activity: 
Peezy Midstream is on the NHS Supply Chain at 87p; the kit includes Peezy funnel, collection tube (choice of 10ml or 30ml) and hygienic wipe for use prior to specimen collection; this will remove surface genital bacteria and debris, which can exacerbate specimen contamination. Ten Peezy kits can be used for the price of one laboratory analysis at the average DH/NHS tariff rate of £8.86.
What is the intellectual property status of your innovation?:
Full patent granted in most global territories; Peezy name and logo are trademarked.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Giovanna Forte 01/03/2018 - 13:35 Archived 1 comment
Innovation 'Elevator Pitch':
Prodlytic is a low cost, scalable tool to provide analytics and insights into how users are using your software and Apps or to investigate big NHS datasets.
Overview of Innovation:
Prodlytic – Analyses information via auto-tracking everything your users do (Staff or patients) whilst using your App or software. No more guesswork, coding, or painful waiting around for data to instantly understand user behaviour, problems with navigation or software, assisting you to make better, faster decisions about the user or your software.

Prodlytic supports instant retroactive analysis, each time a user interreacts with the Software/App the event/action is logged. Thus all events are recorded from the time when ‘Prodlytic’ is added to a system up to the last tracked interaction is displayed.

Thus from adding one line of code to your products and you can answer:
  • When did the user login/sign up to use or access our product/service?
  • How many active minutes do they spend with us? Or how long did it take a user to enter an answer or respond?
  • Where do they spend the most time? Where do they spend the least? What proxies predict this behaviour?
  • How did they navigate or in what order did they select items?
  • How does their behaviour change over time? Are the delays to answering questions, taking long or this changed since last time?
  • When or where do they stop using our service? Highlighting the potential for a follow up or possibly needs a red flag to the clinical team?
 This technology has been used by leading car manufacturers to understand how their in car entertainment (ICE) is being used and by TV set top box providers to understand viewing and selection habits.
 
Hence are you making the most of your user data?

Do you Analyse the usage of your Apps or software.
We can provide information in a simple to understand way from your existing software tools and systems via Dashboards and reporting systems. To improve patient support and engagement to understand where they and staff have difficulties or delays in using your software. Which will help you in either amending and improving the systems and processes or indicate that the user needs help – training or medical.
 
Thus allowing greater efficiency and user satisfaction.
 
We can help you look at what kind of data do you have and what kind of data should you have? Our products can deliver a data strategy or AI (Artificial Intelligence) / ML (Machine Learning) strategy to supercharge your data-informed organisation.
 
Prodlytic offers these tools out of the box, cheaply and scalable.
 
Thus helping organisations turn data into actionable insights
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
The Prodlytic tools allows a NHS organisation or clinical team to understand the issues in using or engaging with a digital platform and will give an insight into their users. Whether that’s to:
  • Identify patient and staff usage – when and how often and for what purpose
  • Understand issues related to using the software.
  • Identify patients that may be indicating clinical problems or changes to their condition due to the usage analytics. Such as:
    • Delays in entering data and changes over time to this behaviour e.g.: If the App asks ‘How are you feeling?’  and they take a long time to indicate ‘OK’ or significantly longer than previous then this may indicate that things are not OK or they are struggling to answer. 
Thus patients can be flagged for investigation or intervention, prior to them calling or recognising that their condition has changed. Leading to improved outcomes and potentially saving money where intervention has ensured that an A&E visit or other catastrophic event has been avoided.
Costs related to the time for staff or patients to use software can be noted and any sticking points highlighted for review. 
Greater values can be gained from insights into use and external effects etc. and related costs can be achieved by combining data from multiple sources, or aggregation of data from different systems, analysis of complex information into meaningful reports or dashboards.

We are aware this will require gaining various NHS data governance permissions to do this work and will work with organisations to ensure they are fully compliant.

Note: This Meridian submission is only looking at single data sources, additional benefits can be gained from multiple data sources or utilising it within data repositories.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Better data-informed decision making leads to better clinical outcomes for WM patients - and a better working experience for NHS staff both outcomes will lead to cost savings.

The true value and range of actual benefits will depend upon the number of applications and systems Prodlytic is applied to.
Current and planned activity: 
Not NHS active at present 
 
We are looking for organisations to work with to demonstrate the value and benefits of our technology in improving the users experience, the performance of their software and to gain insights into the valuable information they have and have access to but have not yet realised it. 
 
By using our analytics to spot trends in an automated way, we could help prevent patients mental health deteriorating, saving repeat visits, reducing costs and improving patient experience.
What is the intellectual property status of your innovation?:
Proprietary closed-source codebase owned by D4Software with some open-source contributions published and more planned.

Prodlytic follows industry best practise and is subject to regular third party security audits. Our codebase is totally private. Open-source contributions to some parts of the system are correctly licenced where applicable.
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Will Grant 05/04/2018 - 15:35 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
​​​This innovation empowers chemotherapy patients to undertake leucocyte monitoring in their own home. A small-scale trial has been completed showing positive feedback from patients, clinicians and carers potentially saving time, lives and money.
Overview of Innovation:
Dignio helps Health Providers (Hospitals, Clinics, Home Nursing etc) to achieve better outcomes for their patients and reduce the need for traditional face to face consultations and admissions via an integrated Telehealth, Remote Patient Monitoring, eCBT and ePROMs platform.
The side effects of chemotherapy seriously impact cancer patients’ daily lives. Managing them effectively is a long-time concern for doctors and clinicians.
Dignio Prevent is a secure, off-the-shelf, cloud based, device agnostic, Remote Patient Monitoring and Telehealth Solution. Dignio can be deployed very quickly with no input from, or impact on, current IT structures, software or licensing services. For chemotherapy patients Dignio can provide a complete remote patient vital signs monitoring solution which included an innovative, Bluetooth enabled, home based, white blood cell monitoring device.
By combining daily Remote Patient Monitoring of vital signs with CBT and frequent home based white blood cell measurement, healthcare providers can follow the patient in real-time and quickly catch any deterioration in the patient’s health and decrease the number of outpatient visits and reduce chance of hospital re-admission. 
Patients and their carers prefer to be at home, they feel more secure, more in control and less stressed. They begin to learn about and understand how they are responding to chemotherapy and begin to modify their behaviour and manage themselves.
This solution can be delivered on a "per patient per month" subscription basis.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Instances of Cancer are increasing and it is estimated that there will be 300,000 new diagnoses a year by 2020. Following publication of the Cancer Taskforce report in July 2015 there is pressure to drive down waiting times, increase diagnostic capacity and reduce outpatient visits.

Dignio Prevent can help healthcare providers to quickly catch any deterioration in a patient’s health helping to reduce treatment cost, decrease hospital readmission and improve patient experience and outcomes saving time, saving lives anbd saving money.
Online Discussion Rating
5.00 (1 ratings)
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Every year, around 31,300 people are diagnosed with cancer in the West Midlands.
The Children’s Cancer Trials Team at the University of Birmingham-based Cancer Research UK Clinical Trials Unit is the only one of its kind in the UK.
Birmingham is at the forefront of childhood cancer research with the team engaged in ground-breaking cancer research, testing and clinical trials across the UK and internationally.
By combining daily remote monitoring of both somatic vital signs and mental health combined with frequent white blood cell measurement at home we can follow the patient almost in real-time and quickly catch any deterioration in the patients’ physical and mental health and decrease the chance of hospital re-admission.
Current and planned activity: 
We are currently engaged with the NHS Test Bed program across a number of use cases in multiple NHS regions.
What is the intellectual property status of your innovation?:
Source code is protected, UI design protected, branding protected
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Ken Garner 25/04/2018 - 10:06 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
We're developing an Autonomous Patient Observation System (APOS) which will automate patient observation in any environment.
Overview of Innovation:
We're a start-up creating an Autonomous Patient Observation System (APOS) which collects user data from facial expressions, physical activities, gait analysis, user habbits, agression and agitation, and so on. We're looking to provide a fully autonomous device which can gather all that data and generate reports, insights, classifications and statistical analysis.
The APOS device is the size of a can of beer, and is extremely easy to use; just register the patient, and let it work for as long as you need to. It does not use cameras, but only lazer depth sensors, and the final product will be low-cost. The APOS device aims to provide impartial, aggregated meta-data and insights, in order to make assessments and evaluations simpler, faster and more accurate.
We're focusing on a Dementia Observation System, and are also interested in frailty indexing. We will be releasing the beta product end of September, and if you would like to test one for free, please contact us.

You may find more information on our website: https://www.mechion.com
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Innovation and adoption
Benefit to NHS:
  • cost reduction because less workforce is needed to monitor and observe patients
  • time reduction because the task of observing and monitoring becomes automated
  • better quality of service: assessments become more accurate and decions more informed due to big data acquisition
  • product could potentially be used in homes, thereby reducing the need of placing patients in facilities
  • earlier diagnosis could be possible, remote diagnosistics and low-cost observation regardless of facilities
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
  • better quality of service received, since more data is collected on a 24/7 basis
  • reduction of costs will allow care-workers and nurses to focus on more important tasks, thereby helping the patients more
  • better and earlier diagnostics can potentially help patients sooner
  • patients could avoid hospitalisation, and be monitored from home
Current and planned activity: 
We are currently engaging international organisations (research clinics and Universities) but are looking for early adopters in the Midlands. We have interviewed and identified key problems and issues we can solve with machine learning and AI and are now moving into prototyping. We should have a beta product ready for testing end of September.
What is the intellectual property status of your innovation?:
Software and Hardware
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
4
Read more
Hide details
Alexandros Gkiokas 16/05/2018 - 12:50 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
UK developed patient focused Population Health solution pulls cross sector data (i.e. GP, Acute, Mental health, etc) and performs analytics and intelligent cohort finding that can identify patients with reported unexplained symptoms.  
Overview of Innovation:
ArtemusICS supports a health system to analyse population data and identify specific gaps, health inequalities and unwarranted variations in its population’s health. ArtemusiCS secure web accessed hosted system provides a wide range of tools, dashboards, selection and filtration options to identify and create patient cohorts. ArtemusICS can then further identify costs, utilisation and gaps in care.

Collecting data from Acute, GP, Community, Mental, Social and Ambulance, ArtemusICS provides commissioners and providers with a tool to identify cohorts of patients, and understand the integrated care needs of a population right down to an individual. It contains analytical tools to allow for LTC risk, EOL risk, Frailty, Social isolation, etc to be collated and presented in one picture. It also allows for evaluation of interventions (i.e outcomes) and identification of RoI.

It has a unique attributes based architecture, where all data items are linked to one or more “attributes”, based on their coding (i.e. Snomed, Read, ICD10, etc). Inherently future proof and expandable, it allows us to utilise Machine Learning and AI techniques to drill through large data sets to find correlations and trends in specified data types, such as the symptoms presented in the MUS cohorts.

ArtemusICS operates on three distinct levels:
  • Overview Dashboards: provide whole-population analytics with facilities to filter down to key patient cohorts. A range of Dashboards provides commissioners and clinicians pertinent population count, event counts, service and usage counts and costs; with the facility to then drill through to cohort and patient specific views.
  • Cohort Manager enables the user to review sub-lists of patients, caseload management groups or individual patients against a range of detailed views including conditions, events, measures, timelines and management lists. Venn diagrams offering cohort comparisons to enable care planners and clinicians to pin-point a specific cohort with a specific set of attributes for intervention and care management.
  • Patient view provides a range of views specific to patient conditions, medications, diagnosis, events and measures, supporting the clinical user to improve diagnosis and plan care.
In addition, our remote monitoring technology can also collect surveys such as PHQ,GAD7, HADs etc
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
ArtemusICS currently identifies all patients with a mental health condition, including those with unexplained medical symptoms; this achieved by the use of Read, SNOMED and ICD10 codes.   Through the development of artificial intelligence and the use of inferential statistics, we would be able to provide rich case finding and provide greater insight in the nature of the specific problem associated with the patients.
Repeat admissions, vague multiple comorbidities and results of screening are all available in the ArtemusICS database and could inform the AI development. Using the ArtemusICS impactability management module, commissioners will be able to assess adherence to care pathways and also monitor the impact of the given interventions.
As patients with medically unexplained symptoms are often seen in multiple care and social settings, ArtemusICS would create and provide a clear picture of all the cross sector activities associated with the patients in order to develop bespoke interventions.
This affords both primary (and potentially) secondary care clinicians the opportunity to introduce patients to a specific MUS care pathway that will deal with the specific requirements of MUS in a timely manner that will prevent the condition becoming chronic.  Effective stratification of patients could aid in a reduction in need for acute secondary care outpatients, reducing unnecessary healthcare costs and freeing up resources.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
As for the health system above
Current and planned activity: 
Docobo are continuously adding additional functionality to its solutions, usually to meet the requests from our NHS customers or our own staff
The uniqueness of ArtemusICS is that Docobo fully owns and controls all of the product. It is not a 3rd party product that we sell, like many others, so we can easily add functionality and are not at the mercy of the overseas priorities of a 3rd party product
What is the intellectual property status of your innovation?:
Fully owned by Docobo
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
3
Read more
Hide details
Adrian 23/05/2018 - 18:42 Publish Login or Register to post comments
6
2
Votes
-99999
Innovation 'Elevator Pitch':
Early identification lies at the heart of the Mental Illness Prevention strategy. PredictX’s proven machine learning model for identification of not school ready children forms the basis for wider application.
 
Overview of Innovation:
The “Get It Right, First Time” program is an ambitious effort to transform the mental health treatment to focus more on early diagnosis and intervention. The benefits of early intervention are clear and well documented. PredictX (PX) believe that we can the application of Machine Learning (ML) based systems improves the identification of at-risk individuals, especially children.

At Essex CC, we developed and deployed a working ML system to identify children and households where the children had a higher probability of not being school ready. As the report states, “ the most productive and cost-effective element of any prevention of mental ill-health strategy will be during a child’s early years.”  The PX school readiness model has proven to be effective in the early identification of not school ready children - beyond previous methods. The system not only identifies at-risk children for early intervention but also indicates the most impactful intervention for a locality.

The PX model not only applies to school readiness but is a flexible framework that adapts to new use cases and available data to solve other similar challenging issues. The model uses data from housing, education, social care, police, health, benefits, and population can use this data for applications beyond school readiness. For instance, early work suggests that the model will be effective predicting domestic abuse - another causal precursor of childhood mental health issues. Because such a wide range of data is accessed, the model is resilient to sparse or missing data from any particular data source.

We believe that the school readiness model is one branch among several that leads to a much more holistic and accurate identification of individuals, families, and locations at risk of mental health issues. Moreover, the model can be tuned to further identify those who would be positively impacted by intervention thus aiding the most effective resource allocation of the intervention team.

The model has the further advantage of having real-world analogues and explainability.  This means that the model will aid the experts by identifying the key causal factors most prevalent in a particular locality, thereby systematically aiding the work with Schools and Education to identify the most critical vulnerabilities and risk markers for mental illness and aiding building the most impactful preventative resilience and wellbeing practices.

Please see:https://youtu.be/3J2S82vjb8U
 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The Five Year Forward View for Mental Health (2016) states that “the future health of millions of children, the sustainability of the NHS, and the economic prosperity of Britain all now depend on a radical upgrade in prevention and public health.” Further it warns that the circumstances since the Wanless review published 12 years ago has become worse. “Mental health problems account for a quarter of all ill health in the UK. Despite important new developments in mental health research it receives less than 5.5 per cent of all health research funding. Latest figures suggest that £115 million is spent on mental health research each year compared with £970 million on physical health research.”  The paper also clearly articulates the importance of Innovation to tackle current and future challenges. In particular , “We see a pivotal role for digital technology in driving major changes to mental health services over the next five years”. Better prevention tools based on AI and Machine Learning is inline with this thinking.

Twelve years ago Derek Wanless’ health review warned that unless the country took prevention seriously we would be faced with a sharply rising burden of avoidable illness. That warning has not been heeded -and the NHS is on the hook for the consequences.”

One of the few silver linings to commencing this work today rather than a decade ago is that the AI technologies to deliver advanced risk identification capability is fully proven now whereas twelve years ago, the technology was nascent if it existed at all.  Therefore the ability to execute the goal of the “Get it Right, First Time” agenda is now feasible with excellent ROI.
 
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
According to Mental Health In The West Midlands Combined Authority, a report commissioned by the  West Midlands Mental Health Commission,  Nearly a quarter of adults living in the WMCA are experiencing a mental health problem at any one time. The report also documents that the cost of mental health problems in the WMCA is estimated at around £12.6 billion in 2014–15, equivalent to a cost of about £3,100 per head of population.

Clearly these challenges and the significant benefits for addressing these challenges are key drivers behind the initiatives already in place in the region.

Identification of at risk individuals, especially children must go hand in hand with the infrastructure to intervene for maximum impact. The work by the West Midlands Academic Health Science Network (WMAHSN) supported by Forward Thinking Birmingham to construct the Proof of Concept program that incorporates partners across health and social care, education and policing, as well as community resources suggests that the program will have the resources and focus to execute the intervention strategies.

The effectiveness of the ML model depends on the access to data. Part of the success of the Essex School Readiness project is the buy-in of the different service areas to share their data to achieve the overall aims of enabling a prevention-based service culture.  West Midlands is ahead with forward thinking localities already sharing data across social care and health. This is a promising position from which extension of data sharing to include education, environment and other key information can develop.

From a PredictX perspective, there is already good working relationships with many of the local authorities in the region including integrated social care data - one of the key elements of the ML model.

This work has been performed in collaboration with the Midlands and Lancashire CSU. The close and strategic working relationship established over many years between PredictX and the Midlands and Lancashire CSU will help to ensure that projects are executed per agreed scope and delivered on time and on budget.
 
Current and planned activity: 
PredictX works with the NHS at several levels currently. We work directly with Provider Trusts such as UCLH supplying them with advanced analytic solutions. We also work with CCGs and STPs focusing on advanced analytics that need to integrate social care and health information. We also work with Local Authorities and regions such as the School Readiness system with Essex CC.

We also have a strategic partnership with the West Midlands CSU working to serve their CCG members as well as investing in research and development efforts to apply Artificial Intelligence and Machine Learning techniques to address challenges the sector faces. This partnership has recently been codified with the launch of the Midlands and Lancashire Innovation Partnership - a partnership of the CSU, private sector and academia working together to deliver advanced, AI-enabled solutions.
 
What is the intellectual property status of your innovation?:
IPR is 100% the property of PredictX with no conflicts. We are happy to co-create new IPR with the sector and share the innovation
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
2
Read more
Hide details
Keesup Choe 30/05/2018 - 09:57 Publish 1 comment
6
2
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 15:11 Publish 4 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
ISL has recently developed a Clinical Trial platform that could be used for collaboration by multiple institutions including NHS/Academia/Pharma/Industry.  Shared protocols, intelligent workflows and secure data management underpin the solution.
Overview of Innovation:
Ensuring your data is accurate, your samples are viable and your results are verifiable are essential when managing clinical trials and carrying out research.

Achiever Medical provides your laboratory with the functionality to manage data quality and integrity, an audit trail to help you assess the quality of your samples and a workflow tool to help map your processes into the solution, including managing the approvals process.

  • Clinical trial functionality to allow easy adoption and customisation for launching and building up clinical trial datasets
  • Manage cohorts, studies, samples, visits and results within a single system that can be shared amongst all collaborating parties
  • One system across multiple institutes, pharma, industry and academia
  • Management reporting cross centre
  • Create and deliver trials quickly with customised data requirements
  • Enforce trial protocols to promote quality and single approach
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health / Innovation and adoption
Benefit to NHS:
  • Rapid rollout of system to support data capture of clinical trials
  • Modify processes and protocols per clinical trial with minimal recourse to IT
  • Share data regionally/nationally across trials
  • Role based permissions to protect data
  • Single system to administer
  • Adapt processes and protocols for trials quickly
Assess Sample Viability
Ensuring you are carrying out research on viable samples is essential when validating any results.  Achiever provides a comprehensive audit trail against each sample including complete details of storage location history (with a temperature audit),  sample check out history (when, by whom, how long and for what purpose) and sample processing history (with sample collection date/time, processed date/time).  A complete sample family history is also available for managing aliquots with related samples (including parent) accessible with a single click.
 
Maintaining Confidentiality
Confidentiality is not only critical when handling patient information but is also a legal requirement.  Achiever offers flexible, secure data protection options to restrict access to identifiable and sensitive information to authorised users only.  Data encryption routines encrypt data at source whilst data security filters only allow authorised users access to selected information within the system.
 
Managing Studies and Workloads
Define studies within the Achiever system and link team members along with their relevant roles.  Generate activities to create and manage workloads with a graphical calendar available to view team schedules.  Monitor and track equipment and consumables used. Capture analyses and results along with any associated documentation and images.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
  • Make clinical trials available quickly to patients within the WM region
  • Ease of reporting to present efficacy of trial within the region
  • Show proactivity of centres and success in recruiting potential volunteers for trial
Current and planned activity: 
The functionality is being rolled out within a Health Trust in the East of England.  The company now wishes to find a national / regional opportunity that would benefit from a single system to promote trials.
What is the intellectual property status of your innovation?:
Released.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Sandie Shokar 30/08/2018 - 15:55 Publish 2 comments
0
0
Votes
-99999